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Aspartylglycosaminuria (AGU),
an inherited lysosomal storage
disease, is caused by the deficient
activity of a lysosomal enzyme 
glycosylasparaginase (GA).
Loss of GA activity results in the 
accumulation of glycoasparagines 
in tissues leading to progressive 
psychomotor retardation and a shortened 
life span. Currently there is no cure for 
AGU. In this study, the effectiveness of 
enzyme replacement therapy (ERT) with 
human recombinant GA was evaluated in 
the mouse model of AGU. Furthermore, 
the enzymatic properties of GA and 
bacterial asparaginases were compared.
This study reveals new therapeutic
and catalytic properties of human GA
and bacterial asparaginases. 
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ABSTRACT 
Glycosylasparaginase (GA) is a lysosomal enzyme which cleaves the linkage between N-
acetylglucosamine and L-asparagine in asparagine-linked glycoproteins. The deficiency of GA in 
aspartylglucosaminuria (AGU) patients leads to progressive psychomotor retardation and a 
shortened life span due to the massive accumulation of aspartylglucosamine (GlcNAc-Asn) and 
other glycoasparagines into tissues and body fluids. Currently there is no curative therapy available 
for AGU. Development of treatment strategies is challenging due to the fact that AGU also affects 
the central nervous system (CNS). 
In the first part of the present study, the effectiveness of enzyme replacement therapy (ERT) with 
human recombinant GA was evaluated in the mouse model of AGU by using biochemical methods. 
It was found that intravenously administered GA effectively cleared GlcNAc-Asn from the non-
neuronal tissues of the treated adult AGU mice, and surprisingly, to some extent also from brains. 
Moreover, a glycoasparagine Man2GlcNAc2-Asn was present as high concentrations in the non-
neuronal tissues of the untreated AGU mice, whereas its accumulation in brain was negligible. The 
level of Man2GlcNAc2-Asn in liver and spleen increased with age of the mice, but no such similar 
trend was found in other tissues. ERT with intraperitoneal injections of GA effectively removed 
both GlcNAc-Asn and Man2GlcNAc2-Asn from non-neuronal tissues of adult AGU mice. 
In the second part of the study, the enzymatic properties of GA and asparaginase were 
compared. In addition to GlcNAc-Asn, GA is known to hydrolyze β-aspartylpeptides. Encouraged 
by the structural similarity of GA and bacterial asparaginases, it was possible to demonstrate that 
bacterial L-asparaginases, which are used in the treatment of acute lymphoblastic leukemia (ALL), 
are also able to catalyze the hydrolysis of certain β-aspartylpeptides, especially small size β-aspartyl 
amino acid amides in vitro. The results suggest that therapy with bacterial L-asparaginases may 
affect the degradation of β-aspartylpeptides in human body and may probably cause some of the 
side effects. 
Due to the fact that GA has similar L-asparaginase activity as the bacterial L-asparaginases used 
in ALL therapy, it was hypothesized that GA might be able to induce apoptosis in leukemia cells in 
vitro. By hydrolyzing the L-asparagine reservoirs, GA induced cell death especially in B-lineage 
ALL cell culture, and less efficiently in T-lineage ALL cells, in a comparable manner with bacterial 
L-asparaginases. It was also found that human recombinant GA depleted effectively both intra- and 
extracellular reservoirs of L-asparagine in the EBV-transformed GA-deficient lymphoblast culture. 
This study provides new insights into the enzymatic and therapeutic properties of 
glycosylasparaginase suggesting that since it is an endogenous human protein, it might be 
applicable as a potential anti-cancer agent as well as being used in the therapy of AGU. 
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TIIVISTELMÄ 
Aspartyyliglukosaminuria (AGU) on suomalaiseen tautiperintöön kuuluva peittyvästi periytyvä 
lysosomaalinen kertymäsairaus, joka johtuu mutaatiosta glykosyyliasparaginaasi-geenissä. 
Glykosyyliasparaginaasi-entsyymin puuttuminen aiheuttaa aspartyyliglukosamiinin ja muiden 
sokerijohdannaisten kertymisen elimistön soluihin, mikä johtaa henkisen ja fyysisen suorituskyvyn 
heikkenemiseen ja lopulta vaikeaan kehitysvammaisuuteen ja ennenaikaiseen kuolemaan. Tällä 
hetkellä AGU-tautiin ei ole parannuskeinoa. Hoitomenetelmien suunnittelu ja toteutus on 
haasteellista, sillä AGU vaikuttaa myös keskushermostoon. 
 Väitöskirjan osatavoitteena oli selvittää entsyymikorvaushoidon tehokkuus AGU-hiirissä. 
Soluviljelmässä tuotetulla rekombinantilla glykosyyliasparaginaasi-entsyymillä hoidettujen 
aikuisten AGU-hiirten kudosten aspartyyliglukosamiinipitoisuus aleni merkittävästi varsinkin 
suurilla entsyymiannoksilla. Glykosyyliasparaginaasi-entsyymin aktiivisuus kohosi kaksi viikkoa 
kestäneen hoidon jälkeen myös aivoissa johtaen aspartyyliglukosamiinikertymän osittaiseen 
alenemiseen. Lisäksi tutkimuksessa havaittiin, että AGU-hiirten kudoksissa aivoja lukuun ottamatta 
oli merkittäviä määriä mannoosia sisältävää aspartyyliglukosamiinia (Man2GlcNAc2-Asn), jota on 
aiemmin löydetty myös AGU-potilaiden virtsasta ja maksasta. Man2GlcNAc2-Asn -pitoisuuden 
havaittiin kohoavan AGU-hiirten perna- ja maksakudoksessa iän myötä. Glykosyyliasparaginaasi-
hoito alensi tehokkaasti myös Man2GlcNAc2-Asn -kertymää. Tulokset rohkaisevat kokeilemaan 
pidempikestoisempaa entsyymikorvaushoitoa vastasyntyneillä AGU-hiirillä, joiden veriaivoeste ei 
ole vielä täysin kehittynyt. Näin ollen entsyymin pääsy aivoihin olisi tehokkaampaa. 
Väitöskirjan toisessa osassa vertailtiin glykosyyliasparaginaasin ja rakenteellisesti sen kaltaisen 
entsyymin, asparaginaasin, entsymaattisia ominaisuuksia. Glykosyyliasparaginaasi-entsyymin on 
aiemmin todettu pilkkovan aspartyyliglukosamiinin lisäksi β-aspartyylipeptidejä, joten niitä 
kokeiltiin myös asparaginaasin substraatteina. Bakteereista eristettyjä asparaginaaseja käytetään 
akuutin lymfaattisen leukemian (ALL) hoidossa, mutta niiden käyttö aiheuttaa vakaviakin 
sivuvaikutuksia. Tutkimus osoitti, että leukemialääkkeinä käytetyt bakteeriperäiset asparaginaasit 
kykenevät pilkkomaan viittä testatuista β-aspartyylipeptideistä, joten osa asparaginaasi-terapian 
aiheuttamista sivuvaikutuksista saattaa johtua β-aspartylpeptidien pilkkoutumisesta.  
Glykosyyliasparaginaasilla on asparaginaasi-entsyymin kaltaisia ominaisuuksia, koska se 
kykenee pilkkomaan asparagiinia aspartaatiksi. Kyseinen ominaisuus kannusti kokeilemaan 
glykosyyliasparaginaasia mahdollisena leukemialääkkeenä. Soluviljelytutkimus osoitti, että 
glykosyyliasparaginaasi tuhoaa B-tyypin ALL-leukemiasoluja yhtä tehokkaasti kuin 
leukemialääkkeinä käytetyt asparaginaasit. T-tyypin ALL-leukemiasolut puolestaan olivat 
resistentimpiä kaikille kokeilluille entsyymeille, mutta glykosyyliasparaginaasi aiheutti ohjelmoitua 
solukuolemaa, apoptoosia, myös niissä. 
Tämä väitöskirjatutkimus antaa uutta tietoa glykosyyliasparaginaasin entsymaattisista ja 
terapeuttisista ominaisuuksista. Tulosten perusteella ihmisperäistä glykosyyliasparaginaasia 
voitaisiin mahdollisesti käyttää osana AGU- ja leukemiapotilaiden hoitoa. 
Luokitus: QU 55, QU 135, WB 330, WD 105, WH 250 
Yleinen suomalainen asiasanasto: entsyymikorvaushoito; entsyymit; aspartyyliglukosaminuria; 
rekombinanttiproteiinit; koe-eläimet; hiiret; leukemia; soluviljely; ohjelmoitunut solukuolema 
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 1  Introduction 
Glycoproteins have diverse roles in many biological functions, such as host-pathogen 
interactions, protein targeting and cell-to-cell contacts. In addition, a variety of glycoproteins 
serve as enzymes, hormones, immunological proteins and structural molecules (Spiro 2002). 
Glycoproteins are polypeptides with covalently linked carbohydrate moieties. According to 
their structure, glycoproteins are divided into two main groups. The O-linked glycoproteins 
have the oligosaccharide chain covalently linked to hydroxyl group (-OH) of serine or threonine 
of protein whereas in N-linked glycoproteins the oligosaccharides are linked to the amino 
group (-NH2) in the asparagine of peptide chain.  
All N-linked glycoproteins contain a common pentasaccharide core structure consisting of 
three mannose residues and two GlcNAc units attached to asparagine of the polypeptide (Fig. 
1). N-linked glycoproteins are further divided into three major families. High-mannose type 
glycoproteins contain various amounts of mannose residues outside the core unit whereas in 
hybrid type N-glycoproteins, the outer oligosaccharide chain contains a variety of sugar and 
amino sugar structures. The complex type N-linked glycoproteins have also sialic acids in the 
oligosaccharide chain (Kornfeld 1985). The folding, localization, immunogenicity and 
bioactivity of a glycoprotein are dependent on its oligosaccharide structure (Moremen 2002). 
 
 
 
 
 
 
Asn-X-Ser/Thr Asn-X-Ser/Thr Asn-X-Ser/Thr 
High-mannose Hybrid Complex 
N N N C C C 
 
Figure 1. The structure of high-mannose, hybrid and complex type asparagine-linked glycoproteins. 
The pentasaccharide core is marked with a grey area. The schematic components of glycoproteins 
are: N-acetyl-β-D-glucosamine (■); α-L-fucose (ᇞ); α- or β-D-mannose ({); β-D-galactose (z) and 
N-acetyl-α-neuraminic acid (). 
 
Glycoproteins are degraded to monosaccharides and amino acids in the lysosomes in a 
bidirectional pathway by over 50 different lysosomal hydrolases. Another set of enzymes, 
exoglycosidases, cleave the monosaccharides sequentially from the non-reducing end of the 
glycoproteins (enzymes 1-6 in Fig. 2). The protein region around the N-glycosidic linkage is 
initially hydrolyzed by proteases, called cathepsins (I). Then, the fucose residue, if present, is 
cleaved by α-L-fucosidase (II). The third enzyme in the stepwise hydrolysis of the protein-to-
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carbohydrate linkage region is glycosylasparaginase (III), which catalyzes the hydrolysis of β-
amide of the Asn-GlcNAc linkage. The release of the reducing end GlcNAc from the di-N-
acetylchitobiose core structure is hydrolyzed either by chitobiase (IV) or N-acetyl-β-D-
glucosaminidase (β-hexosaminidase, enzyme 6) (Aronson 1989) (Fig. 2). 
 
 
Asn C N 
I. Proteolysis 
1. Neuraminidase 
β-Galactosidase 
Asn 
II. α-L-Fucosidase 
3. β-Hexosaminidase 
Asn 
4.  α-Mannosidase 
III. Glycosylasparaginase 
5. β-Mannosidase 
6. β-Hexosaminidase 
or 
IV. Chitobiase 
 
Figure 2. The degradation of Asn-linked glycoproteins in lysosomes. The schematic components of 
glycoproteins are: N-acetyl-β-D-glucosamine (■); α-L-fucose (ᇞ); α- or β-D-mannose ({); β-D-
galactose (●) and N-acetyl-α-neuraminic acid (). 
 
Sometimes one of the specific lysosomal enzymes is totally or partially absent thus causing 
an error in glycoprotein degradation. As a result, incompletely degraded glycoproteins can 
accumulate inside the lysosomes causing many secondary effects such as oxidative stress, ER 
stress, defects in autophagy, altered calcium homeostasis and a significant energy imbalance 
(Hawkins-Salsbury 2011) ultimately leading to slowly or rapidly progressive symptoms and 
death of the patients even in early childhood. The disorders of glycoprotein degradation, the 
corresponding defective enzyme and accumulated products are listed in Table 1. All the 
diseases listed in Table 1 are inherited in an autosomal recessive manner.  
Aspartylglycosaminuria (AGU, McKusick 208400), the most common disorder of 
glycoprotein degradation, is attributable to the deficient activity of glycosylasparaginase (GA). 
The incomplete degradation of glycoasparagines leads to a massive accumulation of 
aspartylglucosamine (GlcNAc-Asn) and other glycoproteins into tissues and body fluids of the 
patients. The clinical features of AGU proceed slowly in childhood, but during the later course 
of the disease, rapid psychomotor retardation occurs usually leading to death before the age of 
40 years. AGU is more common in Finland than in other parts of the world and thus it belongs 
to the Finnish disease heritage (Aula 2001, Arvio 2002).  
α-Mannosidosis is divided into the infantile phenotype (type I) and the juvenile–adult 
phenotype (type II) according to its clinical manifestations and progression. Deficiency of 
functional α-mannosidase (LAMAN; EC 3.2.1.24) leads to an accumulation of the trisaccharide 
Man-α-(1-3)-Man-β-(1-4)-GlcNAc and other oligomannosides to tissues and urine of the 
patients  (Michalski 1999, Caeyenberghs 2006). 
β-mannosidosis, which is caused by deficiency of the enzyme β-mannosidase (MANBA, EC 
3.2.1.25), is very rare; only approximately 20 human cases have been described this far 
throughout the world and a wide range of symptoms of varying degree of severity is observed. 
The lack of the β-mannosidase enzyme causes accumulation of different oligosaccharides 
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Figure 2. The degradation of Asn-linked glycoproteins in lysosomes. The schematic components of 
glycoproteins are: N-acetyl-β-D-glucosamine (■); α-L-fucose (ᇞ); α- or β-D-mannose ({); β-D-
galactose (●) and N-acetyl-α-neuraminic acid (). 
 
Sometimes one of the specific lysosomal enzymes is totally or partially absent thus causing 
an error in glycoprotein degradation. As a result, incompletely degraded glycoproteins can 
accumulate inside the lysosomes causing many secondary effects such as oxidative stress, ER 
stress, defects in autophagy, altered calcium homeostasis and a significant energy imbalance 
(Hawkins-Salsbury 2011) ultimately leading to slowly or rapidly progressive symptoms and 
death of the patients even in early childhood. The disorders of glycoprotein degradation, the 
corresponding defective enzyme and accumulated products are listed in Table 1. All the 
diseases listed in Table 1 are inherited in an autosomal recessive manner.  
Aspartylglycosaminuria (AGU, McKusick 208400), the most common disorder of 
glycoprotein degradation, is attributable to the deficient activity of glycosylasparaginase (GA). 
The incomplete degradation of glycoasparagines leads to a massive accumulation of 
aspartylglucosamine (GlcNAc-Asn) and other glycoproteins into tissues and body fluids of the 
patients. The clinical features of AGU proceed slowly in childhood, but during the later course 
of the disease, rapid psychomotor retardation occurs usually leading to death before the age of 
40 years. AGU is more common in Finland than in other parts of the world and thus it belongs 
to the Finnish disease heritage (Aula 2001, Arvio 2002).  
α-Mannosidosis is divided into the infantile phenotype (type I) and the juvenile–adult 
phenotype (type II) according to its clinical manifestations and progression. Deficiency of 
functional α-mannosidase (LAMAN; EC 3.2.1.24) leads to an accumulation of the trisaccharide 
Man-α-(1-3)-Man-β-(1-4)-GlcNAc and other oligomannosides to tissues and urine of the 
patients  (Michalski 1999, Caeyenberghs 2006). 
β-mannosidosis, which is caused by deficiency of the enzyme β-mannosidase (MANBA, EC 
3.2.1.25), is very rare; only approximately 20 human cases have been described this far 
throughout the world and a wide range of symptoms of varying degree of severity is observed. 
The lack of the β-mannosidase enzyme causes accumulation of different oligosaccharides 
3 
 
 
 
consisting of the disaccharide Man(β1-4)GlcNac and other more complex oligosaccharides 
(Michalski 1999).  
Sialidosis (mucolipidosis type I) is caused by the deficiency of lysosomal sialidase (alpha-N-
acetyl neuraminidase-1, NEU1, EC 3.2.1.18)  and it is classified into two main clinical variants: 
type I, the milder form of the disease, and type II, which can in turn be subdivided into three 
forms: congenital, infantile and juvenile. Excessive amounts of oligosaccharides containing N-
acetylneuraminic acid at the nonreducing terminus occur in the urine of patients (Beaudet 
1989). 
Fucosidosis results from a deficiency of α- L-fucosidase (AFU; EC 3.2.1.51) and leads to the 
accumulation of fucose-containing glycolipids and glycoproteins in many tissues and urine of 
the patients. The major glycopeptide found in urine is Fuc(α1-6)GlcNacβ1-Asn, which can be 
explained by the steric inhibition of the glycosylasparaginase by the fucose residue. A fatal 
infantile form with early mental and motor regression is referred as type I and the milder 
phenotype with adult survival is designated type II (Kau 2011). 
Galactosialidosis is caused by a combined deficiency of lysosomal β-galactosidase and 
neuraminidase, due to a primary defect in protective protein/cathepsin A (PPCA). PPCA is an 
intralysosomal protein that protects both β-galactosidase and α-neuraminidase from premature 
proteolytic processing. Three subtypes of galactosialidosis are recognized: the early infantile 
type, the late infantile type, and the juvenile/adult type (Coutinho 2012a). 
α-N-acetylgalactosaminidase (α-NAGAL, EC 3.2.1.49) cleaves terminal α-N-
acetylgalactosamine residues from glycopeptides and glycolipids, primarily O-linked sugars 
attached to serine and threonine residues. A deficiency of α-NAGAL activity results in the 
accumulation of glycolipids and glycopeptides in Schindler and Kanzaki patients, who suffer 
from neurological and other pathologies (Clark 2009). 
 
Table 1. Disorders of glycoprotein degradation 
Disorder Deficient enzyme Accumulating product Reference 
Aspartylglycosaminuria Glycosylasparaginase 
(aspartylglucosaminidase) 
Aspartylglucosamine and other  
N-linked oligosaccharides 
Aula 2001 
α-Mannosidosis α-Mannosidase Man-α-(1-3)-Man-β(1-4)-GlcNAc 
and other unbranched 
oligosaccharides 
Thomas 2001 
β-Mannosidosis β-Mannosidase Man-β-(1-4)-N- 
acetylglucosamine 
 
Thomas 2001 
Sialidosis  
(mucolipidosis I) 
Sialidase (neuraminidase) Sialyl glycoconjugates Thomas 2001 
Fucosidosis α-L-Fucosidase Fuc-α-(1-2)-Gal-β-(1-4)- 
GalNAc-α-Gal-ceramide 
 
Thomas 2001 
Galactosialidosis β-Galactosidase,  
neuraminidase and  
protective protein/cathepsin A 
Sialyl glycoconjugates d'Azzo, 2001 
Schindler/Kanzaki  
disease 
α-N-Acetylgalactosaminidase Glycopeptides and 
oligosaccharides containing  
α-N-acetylgalactosaminyl  
moieties 
Clark 2009 
 
The above mentioned diseases belong to the glycoproteinoses, a subgroup of lysosomal 
storage diseases, which also includes disorders of lysosomal enzyme phosphorylation and 
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localization. I-cell disease (mucolipidosis II, ML-II) and Pseudo-Hurler polydystrophy 
(mucolipidosis III, ML-III) patients have a defective form of the enzyme N-acetylglucosamine-1-
phosphotransferase and thus the lysosomal enzymes miss their mannose-6-phosphate 
recognition marker and are not targeted to lysosomes. As a result, the lysosomal enzymes are 
secreted into the extracellular medium instead of lysosomes and the affected cells show dense 
inclusions with storage material. Those enzymes are also present in the serum and body fluids 
of affected patients. Pseudo-Hurler polydystrophy is a milder form of I-cell disease 
characterized by a later onset of clinical symptoms and less accumulation of carbohydrates, 
lipids and proteins in the inclusion bodies (Coutinho 2012b).  
A total of approximately 50 lysosomal storage disorders (LSDs) have been identified this far 
and they are divided either according to the type of the accumulating compound or the affected 
lysosomal function. Individual LSDs are rare, but as a group, they are one of the most common 
genetic disorders in children with an incidence of approximately one out of every 7,000-8,000 
live births (Hawkins-Salsbury 2011). Signs and symptoms of these inherited LSDs vary widely 
in severity, even among affected siblings in the same family, and the age of onset ranges from 
infancy to adolescence. Two thirds of the LSDs affect the central nervous system (CNS) and 
mental retardation is common in these patients. The severity of the LSD’s is closely related to 
the residual enzyme activity – the lower the residual activity, the earlier the age of onset 
(Vellodi 2005). 
At present, there is no cure for LSDs but progress has been made in developing effective 
therapies to reduce the clinical symptoms and to improve the quality of life of the patients. One 
general goal of the therapy is to lower the excessive amount of storage material through 
improved substrate degradation, which can be achieved either by hematopoietic cell 
transplantation (HCT) or enzyme replacement therapy (ERT). HCT has proven to be effective in 
MPS I (Hurler disease), α-mannosidosis and Krabbe disease patients, if the procedure is 
performed during early childhood (Beck 2010). However, the major disadvantages of HCT are 
infection, rejection and graft versus host disease (GVHD) which remain the major causes of 
morbidity and mortality following the transplantation (Turbeville 2011). In contrast, ERT is 
generally well tolerated (Beck 2010) and even if the patients develop antibodies against 
therapeutic enzyme in the beginning of therapy they have shown immune tolerance to the 
recombinant enzyme after several weeks of treatment.  
Enzyme replacement therapy replaces the missing or malfunctioning enzyme by frequent 
injections of a recombinant enzyme. The intention is to reduce the accumulating compound 
from tissues and body fluids. The Gaucher’s disease was the first lysosomal storage disease 
successfully treated with ERT and currently there is ERT commercially available for Fabry's 
disease, mucopolysaccharidoses (MPS) I, II and VI, as well as for Pompe's disease throughout 
the world (Rohrbach 2007). All of those abovementioned diseases are non-neuronopathic 
variants of lysosomal storage diseases and naturally the accumulated substrate is more easily 
obtainable for the enzyme than in neuronopathic LSD’s, such as disorders of glycoprotein 
degradation, which face the problem of penetration through the blood-brain-barrier (BBB) 
before the enzyme can exert its therapeutic effect. 
Before ERT is available for the patients, the preclinical studies need to be done either in cell 
culture (in vitro) or with animal models. For some glycoproteinoses, such as fucosidosis and α-
mannosidosis, there exist natural animal models but many of the models have been created by 
so-called knockout techniques. Among glycoproteinoses, there is a knockout mouse model 
available for aspartylglucosaminuria, α- and β-mannosidosis, sialidosis and galactosialidosis. 
Animal models which exactly mimic the LSDs have helped in studying the potential therapies 
for those disorders. Animal models for glycoproteinoses – both knockout and natural ones - are 
listed in Table 2. 
AGU fibroblasts and lymphoblasts have helped to elucidate the efficacy of enzyme 
replacement therapy (ERT) in vitro. For example, recombinant human glycosylasparaginase has 
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proven to be effective in correcting the GlcNAc-Asn accumulation in lymphocytes from an 
AGU patient (Mononen 1995). The mouse models of AGU (Kaartinen 1996, Jalanko 1998) have 
been useful tools when investigating gene therapy and bone marrow transplantation (BMT) as 
potential therapeutic approaches for AGU in vivo. In the mouse model of AGU, a pattern of 
accumulating urinary glycoproteins has been described (Jalanko 1998), yet in tissues their exact 
amounts has not been studied. ERT with AGU has previously been completed only in vitro, in 
cultured AGU lymphoblasts and fibroblasts (Mononen 1995). 
Table 2. Animal models for glycoproteinoses 
 Glycoproteinosis Animal model Reference 
Aspartylglucosaminuria mouse (knockout) Kaartinen 1996  
Jalanko 1998  
 
α-Mannosidosis mouse (knockout) 
cat (natural) 
guinea-pig (natural) 
Blanz 2008  
Vite 2005  
Crawley 2006 
β-Mannosidosis mouse (knockout) 
bovine (natural) 
Zhu 2006  
Jones 1993 
Sialidosis mouse (knockout) de Geest 2002  
Zanoteli 2010 
Fucosidosis dog (natural) Kondagari 2011 
Galactosialidosis mouse (knockout) Bonten 2004  
 
In the first part of this study, a previously devised mouse model of AGU (Kaartinen 1996) 
was used to evaluate whether ERT with human recombinant glycosylasparaginase (GA) would 
have any effect on the storage of aspartylglucosamine (GlcNAc-Asn) in tissues and body fluids 
of these mice.  
Then, the structure of a glycoasparagine, Man2GlcNAc2-Asn, which is also present in AGU 
patients’ urine, was characterized and its concentrations in the tissues and urine of untreated 
AGU mice, and AGU mice treated with human recombinant glycosylasparaginase were 
analyzed quantitatively. Moreover, the effect of ERT on the amount of Man2GlcNAc2-Asn in 
tissues of the treated animals was studied and compared to that of GlcNAc-Asn. 
In addition to its principal substrate GlcNAc-Asn, GA is able to hydrolyze high mannose and 
complex glycoproteins (Kaartinen 1992). Furthermore, it has L-asparaginase activity 
(Noronkoski 1997) and a tetrameric subunit structure rather similar to L-asparaginases 
(Oinonen 1995, Swain 1993). This similarity between GA and L-asparaginase, and the 
observation that GA is able to hydrolyze β-aspartyl peptides (Noronkoski 1998), led to the 
decision to test those peptides also as substrates of bacterial E. coli and Erwinia L-asparaginase.  
Bacterial L-asparaginases, mainly purified from E. coli (EcAII) and Erwinia chrysanthemi 
(ErAII), are used in the treatment of acute lymphoblastic leukemia (ALL). The antileukemic 
effect of L-asparaginase is based on its ability to deplete the extracellular reservoirs of L-
asparagine, which is an essential amino acid to some leukemic cell types. Although bacterial L-
asparaginases have proven effective in ALL therapy, there also exist many disadvantages 
associated with their use. Since the bacterial enzyme is a foreign protein in the human body, a 
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variety of side-effects arise in the patients (Müller 1998). Part of side effects is related to the 
glutaminase activity of L-asparaginase, because the absence of glutamine leads to defective 
nitrogen transportation and insufficient function of liver (Ollenschläger 1988).  
In the last part of this study, encouraged by the L-asparaginase activity of GA, and the fact 
that it does not have any glutaminase activity, the antileukaemic features of human 
recombinant GA were studied in vitro in two different leukemic cell lines that are dependent on 
an external supply of L-asparagine. Furthermore, the ability of GA to hydrolyze both the intra- 
and extracellular Asn reservoirs in vitro was studied using EBV transformed 
glycosylasparaginase-deficient lymphoblasts. 
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2  Review of the literature 
2.1 GLYCOSYLASPARAGINASE 
2.1.1 Discovery 
Lysosomal glycosylasparaginase (aspartylglucosaminidase, EC 3.5.1.26, N4-[β-N-acetyl-D-
glucosaminyl]-L-asparaginase, GA) was found in sweet-almond emulsin in 1964 by Lee et al., 
and it was extracted from guinea pig serum a couple of years later by Makino et al. The 
lysosomal location of GA was first revealed by Mahadevan and Tappel in 1967, when they 
purified the enzyme from rat liver and kidney (Mononen 1997). They also hypothesized that the 
lysosomal activity of glycosylasparaginase might be missing from two mentally retarded 
siblings who excreted GlcNAc-Asn in their urine. In the very next year, the deficiency of GA 
was finally confirmed to be responsible for AGU by Pollitt et al., who observed that GA activity 
was absent from the tissues of those two mentally retarded siblings (Pollitt 1968). After its initial 
purification from rat liver and kidney in 1967, GA has been purified also from human, bovine, 
mouse, pig, chicken (Tollersrud 1992), Sf9 insect cells (Liu 1996) and bacteria (Tarentino 1995). 
2.1.2 Synthesis and structure 
After its synthesis, the inactive single 346-amino-acid GA precursor polypeptide loses its N-
terminal signal sequence of 23 amino acids during the entry into the endoplasmic reticulum 
(ER), and is autocatalytically processed and cleaved into a 27 kDa pro-α-subunit, originating 
from the N-terminal part of the precursor polypeptide, and a carboxy-terminal 17 kDa β-
subunit (Fig. 3) (Saarela 1998). The cleavage of GA precursor polypeptide into pro-α- and β-
subunits exposes the Thr206 (also called Thr183) residue, which is essential for the proteolytic 
activation and enzymatic activity of GA (Saarela 2004a) and has found to be conserved from 
bacteria to mammals. The cleaved, already active enzyme is first delivered to the Golgi 
complex, where mannose-6-phosphate (M6P) is added to each oligosaccharide chain of the 
molecule for lysosomal targeting. Inside lysosomes, GA is further trimmed proteolytically in 
order that it may take on its final heterodimeric or heterotetrameric structure of 24 kDa α- and 
14 kDa β-subunits.  
GA was considered to have a monomeric structure until 1989, when Tollersrud and Aronson 
reported the heterodimeric subunit composition of rat liver glycosylasparaginase. Some years 
later, the cDNA of GA was cloned revealing that one gene encodes two subunits (Mononen 
1997). The human leukocyte enzyme (88 kDA) was found to have a heterotetrameric structure 
by Kaartinen et al. and the three-dimensional structure of GA was described in 1995 by 
Oinonen et al. (Oinonen 1995). According to several studies, GA can exist as both a heterodimer 
and a heterotetramer depending on species and the environmental conditions (Mononen 1997). 
For example, an insect GA from Sf9 cells occurs both as a α2β2 heterotetramer and a αβ 
heterodimer.  
The human lysosomal GA has a heterotetrameric structure, also called αββα-sandwich, with 
dimensions of 50x50x70 Å (Oinonen 1995) (Fig. 4a). The core structure contains a four-stranded 
and an eight-stranded β-sheet packed against each other, and a layer of α-helixes on the outer 
side of both of those β-sheets (Fig. 4b). The heterotetrameric GA has a total of four 
intramolecular disulfide bridges, two of them in the α-subunit (Cys64-Cys69, Cys163-Cys179) 
and another two in β-subunit (Cys285-Cys306, Cys317-Cys345). The α- and β-subunits are 
linked by noncovalent forces (Mononen 1997). 
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heterodimer.  
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Figure 3. Posttranslational trimming of glycosylasparaginase. ER, endoplastic reticulum; SP, signal 
peptide 
 
Glycosylasparaginase has two highly conserved glycosylation sites, Asn38 in α-subunit and 
Asn308 in β-chain. According to monosaccharide analysis of purified human leukocyte 
glycosylasparaginase it contains both high-mannose and complex type N-glycosidic 
carbohydrate chains accounting for approximately 15% of the total enzyme weight. GA of 
human, mouse, pig and cow has been found to be sensitive to endoglycosidase H and alkaline 
phosphatase, which prevent the transfer of the enzyme into lysosomes by removing either the 
high-mannose carbohydrate chains or the phosphate residues, respectively (Mononen 1997). A 
mutation in the β-chain glycosylation site is more important for correct folding and 
transportation into lysosomes than that of α-peptide (Park 1996). The location or number of the 
glycosylation sites of GA in different species shows variation; e.g. in the murine β-chain, the 
carbohydrate is located at Asn310 instead of Asn308, and bovine and rat GA has an additional 
N-glycosylation site at Asn149 of the α-peptide. Sf9 insect GA has its only glycosylation site in 
its α-subunit whereas flavobacterium GA does not have any glycosylation sites at all. 
Each GA heterotetramer contains two funnel-shaped active sites, which bind the asparagine 
portion of the substrates at the narrow bottom and the oligosaccharide part near to the wider 
mouth of the pocket (Oinonen 1995). The binding of aspartylglucosamine to the active site of 
GA is dependent on the presence of a free α-carboxyl group of aspartylglucosamine, whereas 
the α-amino group may be substituted with a group of comparable size (Risley 2001). In the 
active site of human GA, five residues, Arg211, Asp 214, Gly 235, Thr 183 (=Thr206) and Thr 
234, of β-chain make direct hydrogen bonds with aspartate (Oinonen 1995) (Fig. 5). The study of 
Flavobacterium meningosepticum glycosylasparaginase-substrate –complex revealed that the 
binding of the substrate induces a conformational change near to the active site of GA. The 
catalysis is initiated by polarization of the N-terminal Thr152 side-chain by the free α-amino 
group on the same residue, mediated by the side-chain hydroxyl group of Thr170. The cleavage 
of the amide bond is then completed by a nucleophilic attack at the carbonyl carbon of the 
8 
 
 
 
 
 
 
 
 
 Precursor protein (346 amino acids, single chain) 
SP 
 
Monomeric precursor polypeptide  
Pro-D-subunit (27 kDa) E-subunit (17 kDa) 
D-subunit (24 kDa) E-subunit (14 kDa) 
Proteolytic trimming 
Cleavage of signal peptide (SP, 23 amino acids) 
Autocatalytic processing 
ER 
LYSOSOME 
Thr206 
Thr206 
 
 
Figure 3. Posttranslational trimming of glycosylasparaginase. ER, endoplastic reticulum; SP, signal 
peptide 
 
Glycosylasparaginase has two highly conserved glycosylation sites, Asn38 in α-subunit and 
Asn308 in β-chain. According to monosaccharide analysis of purified human leukocyte 
glycosylasparaginase it contains both high-mannose and complex type N-glycosidic 
carbohydrate chains accounting for approximately 15% of the total enzyme weight. GA of 
human, mouse, pig and cow has been found to be sensitive to endoglycosidase H and alkaline 
phosphatase, which prevent the transfer of the enzyme into lysosomes by removing either the 
high-mannose carbohydrate chains or the phosphate residues, respectively (Mononen 1997). A 
mutation in the β-chain glycosylation site is more important for correct folding and 
transportation into lysosomes than that of α-peptide (Park 1996). The location or number of the 
glycosylation sites of GA in different species shows variation; e.g. in the murine β-chain, the 
carbohydrate is located at Asn310 instead of Asn308, and bovine and rat GA has an additional 
N-glycosylation site at Asn149 of the α-peptide. Sf9 insect GA has its only glycosylation site in 
its α-subunit whereas flavobacterium GA does not have any glycosylation sites at all. 
Each GA heterotetramer contains two funnel-shaped active sites, which bind the asparagine 
portion of the substrates at the narrow bottom and the oligosaccharide part near to the wider 
mouth of the pocket (Oinonen 1995). The binding of aspartylglucosamine to the active site of 
GA is dependent on the presence of a free α-carboxyl group of aspartylglucosamine, whereas 
the α-amino group may be substituted with a group of comparable size (Risley 2001). In the 
active site of human GA, five residues, Arg211, Asp 214, Gly 235, Thr 183 (=Thr206) and Thr 
234, of β-chain make direct hydrogen bonds with aspartate (Oinonen 1995) (Fig. 5). The study of 
Flavobacterium meningosepticum glycosylasparaginase-substrate –complex revealed that the 
binding of the substrate induces a conformational change near to the active site of GA. The 
catalysis is initiated by polarization of the N-terminal Thr152 side-chain by the free α-amino 
group on the same residue, mediated by the side-chain hydroxyl group of Thr170. The cleavage 
of the amide bond is then completed by a nucleophilic attack at the carbonyl carbon of the 
9 
 
 
 
 
 
a) 
 
 
chain A and C 
chain B and D 
b) 
c) 
amide linkage in the substrate, leading to the formation of an acyl-enzyme intermediate 
through a negatively charged tetrahedral transition-state (Wang 2007). 
 
 
Figure 4. Three-dimensional structure of human glycosylasparaginase (PDBsum code: 1apy). 
Colours and orientations are modified with RasMol program (Sayle, 1995). a) a spacefill 
representation of GA. Colour codes showing the four chains are green (A), orange (B), blue (C) and 
red (D). A cartoon image of the GA heterotetramer (b) and its two different chains (c) showing the 
secondary structure. Chain A is identical to chain C, and B is identical to D. α-Helices are 
represented in red, β-strands in blue and loops in grey. 
 
 
A diazomethylketone analogue of asparagine, 5-diazo-4-oxo-L-norvaline (DONV), is a 
noncompetitive and irreversible inhibitor of GA due to the formation of an α-ketone ether bond 
with the N-terminal threonine of the β-subunit (Kaartinen 1991). 
2.1.3 Stability, pH optimum, isoelectric point 
GA is extremely heat resistant up to 60 °C and it has a wide pH optimum. Table 3 summarizes 
the pH-optimum, heat stability and isoelectric point of GA of several species. 
2.1.4 GA and the other N-terminal nucleophile hydrolases 
The family of the N-terminal nucleophile hydrolases (Ntn hydrolases) was first described in 
1995 by Brannigan et al. when they reported on the structural similarity of three 
amidohydrolases i.e. glutamine PRPP amidohydrolase (GAT), penicillin acylase and the  
9 
 
 
 
 
 
a) 
 
 
chain A and C 
chain B and D 
b) 
c) 
amide linkage in the substrate, leading to the formation of an acyl-enzyme intermediate 
through a negatively charged tetrahedral transition-state (Wang 2007). 
 
 
Figure 4. Three-dimensional structure of human glycosylasparaginase (PDBsum code: 1apy). 
Colours and orientations are modified with RasMol program (Sayle, 1995). a) a spacefill 
representation of GA. Colour codes showing the four chains are green (A), orange (B), blue (C) and 
red (D). A cartoon image of the GA heterotetramer (b) and its two different chains (c) showing the 
secondary structure. Chain A is identical to chain C, and B is identical to D. α-Helices are 
represented in red, β-strands in blue and loops in grey. 
 
 
A diazomethylketone analogue of asparagine, 5-diazo-4-oxo-L-norvaline (DONV), is a 
noncompetitive and irreversible inhibitor of GA due to the formation of an α-ketone ether bond 
with the N-terminal threonine of the β-subunit (Kaartinen 1991). 
2.1.3 Stability, pH optimum, isoelectric point 
GA is extremely heat resistant up to 60 °C and it has a wide pH optimum. Table 3 summarizes 
the pH-optimum, heat stability and isoelectric point of GA of several species. 
2.1.4 GA and the other N-terminal nucleophile hydrolases 
The family of the N-terminal nucleophile hydrolases (Ntn hydrolases) was first described in 
1995 by Brannigan et al. when they reported on the structural similarity of three 
amidohydrolases i.e. glutamine PRPP amidohydrolase (GAT), penicillin acylase and the  
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Space fill presentation of GA heterotetramer (a), showing the active site in red (another 
active site is located on the other side of the enzyme). Chains A and C are presented in white and B 
and D chains are presented in yellow. Ribbon representation of chain B of GA (b) shows the active 
site residues of human GA as red sticks 
 
proteasome (Brannigan 1995). The structural superfamily members share the unique αββα-core 
structure and they all use serine, threonine or cysteine as a nucleophile in the amino-terminal 
residue of β-sheet which is exposed during the autocatalytic activation. Although there is a 
strong structural similarity in the Ntn-hydrolases, their amino acid sequences exhibit only a 
minor homology. Glycosylasparaginase was recognized as the first mammalian member of the 
family of the Ntn hydrolases by Oinonen et al. (Oinonen 2000). The most recently found 
mammalian Ntn-family members are human acid ceramidase (Shtraizent 2008) and human 
asparaginase-like protein 1 (hASRGL1) (Cantor 2009). The currently known members of N-
terminal hydrolase superfamily and the corresponding substrates and nucleophiles are 
summarized in Table 4. 
 
Table 3. pH-optimum, heat stability and isoelectric point of GA in several species 
Species pH-optimum 
Heat stability 
(ºC) 
Isoelectric 
point Reference 
Human liver 5.5 – 6,  
leukocytes 7 – 9a 
70 5.0 Tollersrud 1992 
aKaartinen 1991 
bKaartinen 1992 
cNoronkoski  1998 
Chicken 5.5 - 6 70 6.8 Tollersrud 1992 
Pig 5.5 - 6 70 5.1 Tollersrud 1992 
Mouse 7 - 8 70 5.3 Tollersrud 1992 
Rat 7 - 9 75 5.3-6.3a, 
6.4- 6.6b 
aTollersrud 1992 
bTollersrud 1989 
Sf9 4 - 10,5 65-70  Liu 1996 
Cow 5.5 - 6 77 6.2 Tollersrud 1992 
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Table 4. Members of Ntn hydrolase superfamily 
Enzyme Substrate Nucleophile    Reference 
Glycosylasparaginase GlcNAc-Asn Thr Oinonen 2000 
Asparaginase (plant) Asn Thr Aronson 1996 
Asn synthetase Gln Cys Aronson 1996 
Glutamate synthase 2-Oxoglutarate,  
L-Glutamine 
Cys Kim 1996 
Proteasome subunit Proteins Thr Aronson 1996 
Cephalosporin acylase Cephalosporins Ser/Thr Kim 2006 
Glutamine 
Phosphoribosyl- 
pyrophosphate (PRPP) 
Amidotransferase 
Gln Cys Kim 1996 
J-glutamyl-transpeptidase Glutathione Thr Okada 2007 
GlcN-6-P synthase Glutamine Cys Mouilleron 2011 
Acid ceramidase HUMAN Ceramide Cys Shtraizent 2008 
Penicillin acylase Penicillin G Ser Aronson 1996 
AcylCoA: isopenicillin 
N acyltransferase 
Isopenicillin N Cys Bokhove 2010a 
Peptidase family U34 Peptides Cys Pei 2003 
PvdQ N-Acyl homoserine lactone Ser Bokhove 2010b 
Lysosomal 66.3 kDa protein Not known Cys Lakomek 2009 
hASRGL1 HUMAN β-Aspartyl peptides Thr Cantor 2009 
2.1.5 Substrate specificity 
 
2.1.5.1 Aspartylglucosamine in N-linked glycoproteins 
The native substrate of GA is aspartylglucosamine (GlcNac-Asn), which is present in the 
carbohydrate-to-protein linkage of N-linked glycoproteins. GA catalyzes the hydrolysis of 
GlcNAc-Asn to 1- amino-N-acetylglucosamine and L-aspartic acid, which are further cleaved 
nonenzymatically to N-acetylglucosamine and ammonia (Fig. 6). 
2.1.5.2 Other substrates 
It has been demonstrated that GA is also able to hydrolyze β-aspartylpeptides (isoaspartyl 
peptides), such as β-aspartylserineamide and β-aspartame (Noronkoski 1998). β-
Aspartylpeptides are present in human urine (Kakimoto 1961, Buchanan 1962) and some of 
them have been found in rat brain tissue (Sandberg 1994). Some of the β-aspartylpeptides are 
believed to represent the end products of protein degradation (Buchanan 1962) and they are 
also considered to be of dietary origin (Pisano 1966). In the synthesis and degradation of the β-
aspartylpeptides, GA has an important role (Noronkoski 1998).  
In addition to GlcNAc-Asn and β-aspartylpeptides, GA is able to hydrolyze non-fucosylated 
high mannose and complex type glycoasparagines (Kaartinen 1992), aspartyl-N-
acetyllactosamine and its sialylated derivatives, as well as L-asparagine (Noronkoski 1997). 
Table 5 summarizes the substrates of GA and the corresponding reaction rates. 
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Figure 6. The hydrolysis of GlcNAc-Asn to GlcNAc-NH2 and L-aspartic acid by glycosylasparaginase 
(GA). The reaction products are further hydrolyzed nonenzymatically to GlcNAc and ammonia. 
 
Table 5. The substrate specificity of glycosylasparaginase. ND, not detected. 
Substrate Relative rate Reference 
Asn-Glc 140 Tanaka et al. 1973  
Galactosylasparagine (Asn-Gal) 101 Tanaka et al. 1973  
N-Aspartylglucosamine (GlcNAc-Asn) 100 Kaartinen et al. 1992  
Tanaka et al. 1973 
Asn-Man 96 Tanaka et al. 1973 
β-N-Acetyllactosamine-L-asparagine  
(GalGlcNAc-Asn) 
88 Kaartinen et al. 1992 
Man9GlcNAc2-Asn 85 Kaartinen et al. 1992 
β-N-Acetylneuraminyl-α2-3-N-acetyllactosamine-L-
asparagine (NeuAcGalGlcNAc-Asn) 
71 Kaartinen et al. 1992 
β-Aspartylserineamide (β-Asp-Ser-NH2) 71 Noronkoski et al. 1998  
NeuAc2Gal2GlcNAc4Man3-Asn 65 Kaartinen et al. 1992 
β-L-Aspartyl methyl ester 63 Kaartinen et al. 1992 
β-N-Acetylneuraminyl-α2-6-N-acetyllactosamine-L-
asparagine (NeuAcGalGlcNAc-Asn) 
53 Kaartinen et al. 1992 
Aspartylgalactosamine (GalNAc-Asn) 49 Tanaka et al. 1973 
β-Asp-Gly-Val (β-aspartylglycinevaline) 49 Noronkoski et al. 1998 
Asparagine (Asn) 41 Noronkoski et al. 1997 
Asparagine (Asn) 45 Tanaka et al. 1973 
β-Aspartylalanineamide (β-Asp-Ala-NH2) 35 Noronkoski et al. 1998 
β-Asp-Gly-Gln 27 Noronkoski et al. 1998 
β-Aspartame (β-Asp-Phe-Ome) 23 Noronkoski et al. 1998 
β-Aspartylglycineamide (β-Asp-Gly-NH2) 15 Noronkoski et al. 1998 
β-Aspartyltetraglycine (β-Asp-(Gly)4-OH) 8 Noronkoski et al. 1998 
β-Aspartylhydroxamate 7,5 Tanaka et al. 1973 
β-Aspartylhydroxamate 4 Kaartinen et al. 1992 
β-Aspartylglycine (β-Asp-Gly-OH) 3 Noronkoski et al. 1998 
L-Asparthydrazide 0,8 Tanaka et al. 1973 
L-Aspartic acid β-(7-amido-4-methylcoumarin) ND Mononen et al. 1993 
2.1.6 Recombinant human glycosylasparaginase 
Recombinant human glycosylasparaginase has been produced in NIH 3T3 mouse fibroblasts 
(Mononen 1997), CHO-K1 cells (Riikonen 1994) and human leukocytes (Tikkanen 1996). The 
large-scale production of human recombinant GA in NIH 3T3 mouse fibroblasts showed that 
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the intracellular level of GA was more than 120-fold than the corresponding activity in 
nontransfected cells. Furthermore, the purified recombinant enzyme was as active as human 
leukocyte GA, although its β-chain is 1 kDa smaller than that of native enzyme. Recombinant 
GA has found to be sensitive to alkaline phosphatase and endoglycosidase H, which prevent 
the transport of GA into lysosomes by removal of phosphate residues or carbohydrates, 
respectively (Mononen 1995).  
2.1.7 Determination of GA activity 
The activity of GA can be detected from biological samples such as blood cells, plasma, serum 
and cultured fibroblasts by a colorimetric or fluorometric method or by high-performance 
liquid chromatography (HPLC). The colorimetric detection of GA by the Morgan-Elson reaction 
is currently not usually performed due to its poorer sensitivity than the other methods. The 
fluorometric assay uses L-aspartic acid β-(7-amido-4-methylcoumarin) as the substrate and has 
40 to 100-fold higher sensitivity than can be achieved with colorimetric method (Mononen 
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aspartylglucosamine in the reaction catalyzed by GA (Kaartinen 1990).  
2.2 ASPARTYLGLYCOSAMINURIA 
2.2.1 Discovery 
The disease aspartylglycosaminuria (AGU, McKusick 208400) was first described in 1968 by 
Jenner and Pollitt when they found abnormal amounts of 2-acetamido-1-(β’-L-aspartamido)-1,2-
dideoxy-β-D-glucose (aspartylglucosamine) in urine of English siblings suffering from mania 
and depression (Pollitt 1968). At the same time in Finland, Professor Jorma Palo screened a large 
number of mentally retarded persons to study the prevalence of phenylketonuria (PKU) in the 
Finnish population, and discovered an abnormal peptide in the urine of nine patients. He 
finally identified the unknown peptide as GlcNAc-Asn after reading the report of Jenner and 
Pollitt. Thereafter, AGU has found to be the most common disorder of glycoprotein 
degradation. Patients with AGU have been reported in several countries around the world, but 
in Finland the disease has a much higher prevalence than elsewhere. In Finland, 1-3 AGU 
children are diagnosed annually. By the end of 2010, a total of 260 AGU patients had been 
identified in Finland. 
2.2.2 Clinical aspects 
Diagnosis of AGU is rarely made before the age of one year because the pregnancy usually 
proceeds without complications and babies appear normal at birth. The early symptoms, such 
as delayed speech, recurrent respiratory infections, stubborn behaviour and clumsiness are 
usually diagnosed before the age of five years. At the age of 13-16 years, the skills of AGU 
patients are at their best and correspond to those of healthy 5-6 -year-old children. However, 
the course of the disease varies individually. AGU proceeds slowly until the age of 25-28 years, 
but during the later course of the disease, coarsening of the habitus, as well as rapid mental and 
motor retardation occurs, and the patients will need continuous help in everyday living. The 
average lifespan of AGU patients is approximately 40 years (Aula 2001, Arvio 1997, Arvio 2002). 
2.2.3 Mutations causing AGU 
AGU is an autosomal recessively inherited lysosomal storage disease meaning that the patients 
have inherited a mutated glycosylasparaginase gene from both of their parents. The human 
glycosylasparaginase gene was localized to chromosome 4q34-35 in 1992 and since then, more 
than 25 different mutations, including splicing and missense mutations, insertions and 
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deletions, have been described, most of them representing rare family AGU alleles (Saarela 
2004b). The double point mutation responsible for 98% of the AGU cases in Finland, AGUFIN, is 
caused by the substitution of cysteine 163 with serine (G488C transition) and substitution of 
arginine 161 with glutamine (G482A transition). The substitution of cysteine is solely 
responsible for the AGU since it causes the loss of one disulphide bridge thus preventing the 
cleavage of the peptide into the active enzyme. The mutated enzyme remains as an inactive and 
misfolded single chain polypeptide and is rapidly degraded already in ER (Aronson 1999). 
Substitution of arginine represents a neutral polymorphism and does not affect enzyme activity 
(Aronson 1999). The minor Finnish AGU allele is a 2-bp deletion in exon 2 of the GA gene, 
which causes a frameshift resulting in a premature stop codon. Heterozygous AGU carriers 
have mutation only in one allele, and they do not suffer from clinical symptoms of AGU (Aula 
2001). The AGUFIN major gene in Finland has shown a carrier frequency of 1 case in 50–85 
(Arvio 2002). 
2.2.4 Biochemistry and diagnosis 
In AGU patients, the deficient activity of glycosylasparaginase leads to the accumulation of 
GlcNAc-Asn and other glycoasparagines in body fluids and tissues. Urinary level of 
aspartylglucosamine can be even 1000-fold higher in AGU patients when compared to healthy 
controls and carriers of the disease (Mononen 1997). In addition, increased amounts of both 
neutral and acidic glycoasparagines are detectable in urine (Pollitt and Pretty 1974). A list of the 
glycoasparagines detected in urine of AGU patients is presented in Table 6.  
Table 6. Glycoasparaginases found to be present in urine of AGU patients 
Compound Reference 
GlcNAc-Asn Mononen 1997  
Man2-GlcNAc2-Asn Pollitt 1974  
Lundblad 1976  
Gordon 1998  
Gal-GlcNAc-Asn Lundblad 1976 
Neutral glycoasparagines  
containing fucose, mannose or galactose 
Fuc-Gal-GlcNac-Asn 
Man2-GlcNAc2-Asn 
Man2-Gal-GlcNAc-Asn 
Acidic glycoasparagines containing  
N-acetylneuraminic acid (NANA) 
NANA-Gal2-GlcNAc-Asn 
NANA2-Gal2-GlcNAc-Asn 
Pollitt and Pretty 1974  
NANA-Gal-GlcNAc-Asn Sugahara 1977  
 
A traditional but still a useful method for the diagnosis of AGU is the detection of 
glycoasparagines from urine with thin layer chromatography (TLC), in which the pattern of 
carbohydrate containing structures can be visualized with either ninhydrin or orcinol. 
Glycoasparagines have been detected also by electrophoresis and paper chromatography, but 
currently HPLC offers a more sensitive, quantitative and faster analysis (Mononen 1997). 
GA activity in the tissues and body fluids of AGU patients have found to be totally absent or 
reduced to less than 10% when compared to healthy individuals. Interestingly, the mean GA 
activity of the AGU carriers is only 25% of the normal lymphocyte activity, but 72% and 75% of 
normal plasma and serum activity, respectively. Due to the overlap in GA activity between the 
normal controls and the carriers of AGU, the determination of GA activity is not reliable for 
carrier detection (Mononen 1994).  
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 The assay of GA activity was initially based on colorimetric detection of the released N-
acetylglucosamine by the Morgan-Elson reaction in the presence of aspartylglucosamine, but it 
was found to be unspecific and the analysis required a long incubation time. Currently, even 
low levels of GA activity can be determined from serum, plasma, blood cells or fibroblasts of 
the patient either by a fluorometric assay using L-aspartic acid β-(7-amido-4-methylcoumarin) 
as the substrate or by HPLC (Mononen 1997).  
The carriers of AGUFIN mutation can be detected from blood by three different polymerase 
chain reaction (PCR) -based methods; oligonucleotide ligation assay, hybridization with allele-
specific oligonucleotides and solid-phase minisequencing (Romppanen 1997). Prenatal 
diagnosis of AGU is based on the assay of GA activity from cultured amniotic cells, chorionic 
villus samples and amniotic fluid, or the identification of the disease-causing mutation in both 
alleles of the GA gene (Mononen 1997). Currently in Finland, the diagnosis of AGU is based on 
DNA methods as well as the detection of urinary oligosaccharides by TLC and HPLC. 
2.2.5 Therapy and animal models of AGU 
After the discovery of the molecular and cellular mechanisms contributing to AGU, the 
strategies for effective therapy have been widely studied. Thus far no curative treatment is 
available, but according to studies performed either in vitro, in AGU mouse model or in human 
patients, enzyme replacement therapy (ERT), bone marrow transplantation (BMT) and gene 
therapy may be potential therapeutic approaches. Early diagnosis of AGU before the onset of 
irreversible pathologies, such as skeletal abnormalities, is essential for effective therapy (Meikle 
2003). 
Two transgenic mouse models of AGU have been generated, one with a targeted disruption 
of exon 3 (Kaartinen 1996) and another having a mutation in exon 8 (Jalanko 1998). Both AGU 
mouse models lack the GA activity and share the typical biochemical and phenotypic 
characteristics of the human AGU disease including the accumulation of GlcNAc-Asn in tissues 
and urine as well as the slow course of the disease (Gonzalez-Gomez 1998, Jalanko 1998). 
Mouse models have proved to be useful in both the investigation of the biochemical 
consequences of the metabolic defect and the development of therapeutic protocols for AGU. 
2.2.5.1 Enzyme replacement therapy 
In AGU, the in vitro studies investigating the efficacy of enzyme replacement therapy have 
been performed in AGU fibroblasts and lymphoblasts leading to the correction of intracellular 
GA activity and the restoration of the GlcNAc-Asn concentration to the normal level (Enomaa 
1995, Mononen 1995). Additionally, it has been demonstrated in vitro that uptake of 
extracellular recombinant GA is possible also by neuronal cells, indicating that ERT may be 
effective in brain tissue (Kyttälä 1998). However, the efficacy of ERT has not been evaluated in 
human AGU patients. 
2.2.5.2 Bone marrow transplantation (BMT) 
Bone marrow transplantation of eight-week-old AGU mice has shown that BMT is effective 
in correcting the pathology of liver and spleen, but not that of brain and kidney (Laine 1999). 
More recent studies with 3-week-old AGU mice have shown that BMT with wild-type donors 
having normal enzyme activity results in total correction of lysosomal vacuolization in liver and 
30-80% reduction of vacuolated neurons in brain (Laine 2004).  
BMT therapy in human AGU patients has also been reported, but the benefits of BMT are 
difficult to predict due to the slowly progressing nature of AGU. A Canadian boy who received 
BMT at the age of 1.5 years, showed a reduced urinary excretion of GlcNAc-Asn and increased 
GA activity in white blood cells for several weeks after therapy, but long-term effects of BMT on 
the neurological symptoms was not reported (Laitinen 1997). Three children carrying the 
AGUFIN mutation underwent allogeneic BMT at the age of 1.5, 2.0 and 2.6 years, and two of 
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them showed improvements in radiological, histopathological and biochemical tests. After the 
follow-up of 3 years, the GA activity in their blood leukocytes was near to that of heterozygous 
level and storage lysosomes had disappeared from the rectal area. Neurological effect of BMT 
was followed by magnetic resonance imaging (MRI), and at the end of the follow-up, the ratio 
of deep grey matter and white matter signal intensities was near to the normal level (Autti 
1997). Furthermore, two AGU children underwent allogeneic BMT at the ages of 2 and 2.6 
years, and slowly normalization of the pathological, biochemical and MRI findings were found 
in both of them during the four and seven years’ follow-up, but no significant progress was 
seen in mental level (Autti 1999).  
In 2001, Arvio et al. reported that some of the patients, who had undergone transplantation 
at the age of 1.6-10.4 years, were even more severely retarded than the non-transplanted 
patients, and several patients experienced from post-transplant complications. Due to the 
unfavourable outcome of those BMT patients, they concluded that transplantation should be 
recommended for AGU patients only in infancy to achieve the best beneficial effect on 
neuropsychological functioning (Arvio 2001). Malm et al. reported the five-year follow-up of 
two human AGU siblings, the same patients which were included in the study of Arvio et al. 
Neither of the children had lost any capabilities since transplantation, the activity of GA in 
leukocytes was normalized and Tau-protein had reached almost normal levels during the 
study, indicating an arrest of the disease. It was also suggested that BMT may prevent further 
progress of AGU disease and may have a positive impact on the quality of life as compared to 
untreated AGU patients (Malm 2004). 
Currently, due to the negligible advantages of BMT in the treatment of AGU, it is not 
routinely used for AGU patients. 
2.2.5.3 Gene therapy 
In somatic gene therapy, the patient’s own cells can be genetically modified in vitro or in vivo 
to express the correcting enzyme (D'Azzo 2003). At the present time, gene therapy of AGU has 
only been tested in vitro and in the mouse model of AGU. After a retroviral in vitro infection, a 
significant, 40-fold, increase in GA activity was achieved in AGU fibroblasts when compared to 
untreated AGU cells, and the activity remained high for at least two months (Enomaa 1995). A 
few years later, Peltola et al. used adenovirus vectors encoding the human GA in the treatment 
of AGU mice. A total correction of lysosomal storage after one month, and an increase in GA 
activity lasting for at least 4 months, was observed in liver by injection of adenoviral vectors 
into the tail vein of AGU mice. An injection of viral vectors directly into the left lateral ventricle 
increased GA activity for 4 months in brain tissue. When recombinant GA was injected 
intraventricularly into AGU mice, the enzyme diffused across the ependymal cell layer lining 
the ventricles leading to partial correction of lysosomal storage in the adjacent brain tissue. 
Similar results were achieved with an intraventricular injection of retroviral vectors indicating 
that even a small amount of transduced cells in brain is able to distribute GA enzyme to the 
neighbouring areas (Peltola 1998).    
Virta et al. used tissue-specific promoters, such as neuron-specific enolase (NSE), in their 
adenovirus-mediated gene therapy study. The viruses were injected directly into the striatum, 
which is an area with connections to several brain areas. As a result, the decrease in lysosomal 
accumulation was evident in wide areas of the brains of the AGU mice (Virta 2006). 
2.3 L-ASPARAGINASES 
L-asparaginase (L-asparagine amidohydrolase; EC 3.5.1.1) is an enzyme that primarily catalyzes 
the hydrolysis of L-asparagine to L-aspartic acid and ammonia (Fig. 7).  
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2.3.1 Discovery 
The hydrolysis of L-asparagine to L-aspartate and ammonia was first described in 1904 by Lang 
and those results were confirmed by Fürth and Friedmann in 1910. In 1922 Clementi reported 
that asparaginase is present only in the liver of omnivorous animals, in contrast to herbivores 
which have asparaginase in practically all tissues. In 1953 Kidd noted that guinea pig serum 
suppressed the growth of lymphosarcomas in mice, and the antileukemic properties of 
asparaginase were recognised for the first time by Broome who confirmed that L-asparaginase 
was the active antitumor component in serum (Broome 1961, Müller 1998, Keating 1993). 
Further studies proved that leukemic cells require extracellular asparagine for their growth and 
metabolism, and L-asparaginase isolated from E. coli and Erwinia chrysanthemi was successively 
used for clinical trials in childhood acute lymphoblastic leukemia (Müller 1998).  
L-asparaginase has been found to be present in chicken liver, yeasts and molds, plants, 
serum of some rodents, in several bacteria (Howard 1972) and in fungal isolates (Shrivastava 
2010), but it is not expressed in humans.  
 
 
 
 
 
 
 
 
Figure 7. Hydrolysis of L-asparagine to L-aspartic acid and ammonia by L-asparaginase 
2.3.2 Structure 
The classification of all L-asparaginases (Fig. 8) is based on their amino acid sequences (Labrou 
2010, Borek 2001). The first class includes the bacterial type L-asparaginases which can further 
be divided into two subclasses. Bacterial type II L-asparaginases are located in the periplasmic 
space of bacteria, whereas type I L-asparaginases are cytosolic. Type II L-asparaginases can also 
hydrolyse L-glutamine and those L-asparaginases which have a greater specificity against L-
glutamine are called glutaminase-asparaginases (EC 3.5.1.38). Members of the second subclass 
exist in plants and are thus named plant-type-L-asparaginases. This group of L-asparaginases 
displays no homology to bacterial-type asparaginases but it shares approximately 60% of amino 
acid sequences with the aspartylglucosaminidases, like glycosylasparaginase, which belong to 
the superfamily of N-terminal nucleophile hydrolases (Hejazi 2002). The structural difference 
between glycosylasparaginase and plant-type asparaginase is the occurrence of two aromatic 
residues, Thr-11 and Phe-13, in the vicinity of catalytic Thr in glycosylasparaginase.  The third 
class of L-asparaginases includes Rhizobium etli L-asparaginases which exhibit no homology 
with the other L-asparaginase classes. 
Type II bacterial L-asparaginases, such as EcAII and ErAII, are highly conserved 
homotetrameric enzymes composed of four identical ~330 amino acid subunits, which consist of 
two α/β domains connected by a linking sequence. The N-terminal domain of each monomer 
contains an eight-stranded mixed β-sheet, four α-helices and a separate β-hairpin positioned 
toward the interior of the tetramer. The C-terminal domain is smaller, and has a four-stranded 
parallel β-sheet and four α-helices (Fig. 9). One unique feature of all L-asparaginases is the left-
handed crossover between strands β4 and β5. The amino acid residues present in crossover 
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Thr89, Asp90, Ala114 and Lys162 from one subunit, and Asn248 and Glu283 from the other 
intimate subunit (Labrou 2010). Water molecules and the hydrogen-bond network formed by 
the side-chains of the active site residues are important for the activity of the enzyme 
(Kravchenko 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Classification of asparaginases 
Figure 9. Three-dimensional structure of native L-asparaginase purified from E. coli (PDBsum code: 
3eca). Colours and orientations are modified with RasMol program (Sayle, 1995). a) The spacefill 
representation of E. coli L-ASNase tetramer. Colour codes for identical subunits are orange (A), 
green (B), blue (C) and red (D). Cartoon representation of L-asparaginase homotetramer (b) and 
one subunit (c) showing the secondary structure elements; α-helices are coloured in red, β-sheets in 
blue and loops in grey. Cartoon representation of the L-ASNase subunit showing the flexible loop 
(residues 12-33) in red. 
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Crystallographic structures of several bacterial L-asparaginases, including E. coli 
asparaginase type II (Swain 1993), Erwinia asparaginase (Aghaiypour 2001) and Erwinia 
carotovora EwA (Papageorgiou 2008) have been determined, but at present no eukaryotic 
enzymes have been characterized. The crystal structure of type I bacterial asparaginase was 
proved to be dimeric by Yao et al. in 2005 (Yao 2005) when this enzyme from Pyrococcus 
horikoshii was characterized. The dimer corresponds to the intimate dimer of EcAII. 
2.3.3 Substrate specificity 
E. coli asparaginase type II, which is located in the periplasmic space of bacteria, has higher 
affinity for L-asparagine than the cytosolic asparaginase type I. E. coli and Erwinia L-
asparaginases, EcAII and ErAII, possess glutaminase activity only 2-9% of that of L-
asparaginase activity (Table 7) (Howard 1972, Campbell 1967, Campbell 1969).  
An isoaspartyl peptidase found in E. coli has been shown to have L-asparaginase activity; its 
amino-acid sequence is homologous to those of plant-type asparaginases and it has a structure 
similar to that of glycosylasparaginase. The E. coli isoaspartyl peptidase undergoes 
autoproteolysis and has a Thr residue as a nucleophile, thus belonging to a superfamily of N-
terminal nucleophile hydrolases, as does the glycosylasparaginase (Prahl 2004). Recombinant 
plant-type asparaginases from the cyanobacteria Synechocystis sp. and Anabaena sp. and from 
the plant Arabidopsis thaliana expressed in E. coli were able to hydrolyze L-asparagine and β-
aspartyl dipeptides, but not GlcNAc-Asn (Hejazi 2002). On the contrary, none of the isoaspartyl 
dipeptide substrates could be cleaved by type II L-asparaginase from E. coli. 
In addition to L-asparagine and L-glutamine, L-asparaginases are able to hydrolyze D-
asparagine (Campbell 1969), succinamic acid, L-aspartate-β-hydraxamate, L-aspartate-
methylester, DL-Nα-ethylasparagine and N4-methoxy-L-asparagine (Herrmann 1974) (Table 7). 
An asparagine analog 5-diazo-4-oxo-L-norvaline (DONV) is both a substrate and an inhibitor of 
L-asparaginase (Jackson 1970). 
Table 7. Substrate specificity of L-asparaginases purified from E. coli and Erwinia carotovora 
 Relative rate (%) 
Substrate E. coli Erwinia 
L-Asparagine 100 100 a  
D-Asparagine 8b 5 a  
L-Glutamine 2-3 b,c  9 a 
D-Glutamine  0,02 a 
Succinamic acid 0 d 20 a 
β-L-Cyanoalanine  5,7 a  
DL-Isoasparagine  0,1 a 
L-Aspartohydroxamic acid  
(L-aspartyl-β-hydroxamate) 
  19 a 
N4-Hydroxyl-L-asparagine 105d   
N4-Methoxy-L-asparagine 20 d  
N4-Methyl-L-asparagine 0,8 d  
N2-Ethyl-DL-asparagine 2,5 d  
Glycyl-L-asparagine 0,5 d   
 
a Howard, 1972 c Campbell, 1967  
b Campbell, 1969 d Herrmann, 1974  
2.3.4 Biochemical analysis 
The determination of L-asparaginase activity from biological samples is commonly based on the 
formation of ammonia from L-asparagine. One unit of asparaginase activity is defined as the 
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amount of enzyme that liberates 1 μmol of ammonia from asparagine per min at 37 °C. The 
liberated ammonia can be detected with a spectrophotometer by using Nessler’s reagent 
(Jackson 1970, Boos 1996, Campbell 1967), Berthelot reaction (Schwartz 1970) or with an 
ammonia gas-sensing electrode (Tagami 1990). Nessler's reagent, a solution of potassium 
tetraiodomercurate(II) in potassium hydroxide, turns to a yellow color in the presence of 
ammonia and at higher concentrations, a brown precipitate may be formed. Berthelot's reagent, 
which is an alkaline solution of phenol and hypochlorite, forms a blue product in the presence 
of ammonia. 
L-asparaginase activity can also be determined by an enzyme coupling method, in which the 
rate of the decline in the absorbance that occurs as a result of oxidation of NADH is measured 
spectrophotometrically (Asselin 1993, Tsurusawa 2004). The hydrolysis rate of L-asparagine can 
also be followed by an amino acid analyzer (Howard 1972) or HPLC (Noronkoski 1997). In 
addition to L-asparagine, alternative compounds such as AspAMC in a fluorometric L-
asparaginase assay (Ylikangas 2000) or 14C-labelled L-asparagine (Broome 1968) and L-aspartic 
β-hydroxamate (AHA) (Lanvers 2002) can be used as the substrate of L-asparaginase.  
2.3.5 Asparaginase in treatment of leukemia 
2.3.5.1 Acute leukemias (AL) 
Acute lymphoblastic leukemia (ALL) is the most common cancer in children but it can occur at 
all ages. In ALL patients, the genetically altered hematopoietic stem cells or their committed 
progenitors undergo dysregulated proliferation and the malignancies arise from lymphoblasts, 
either B- or T-cells. It has been claimed that most of the childhood ALL cases have a prenatal 
origin, and an additional exposure, such as an infection, is required for the initial step in the 
cascade of biochemical events leading to genetic alterations and finally to leukemia (Taub 2004, 
Cazzaniga 2011). 
Due to the advanced molecular and immunological techniques available, ALL can be divided 
into various subtypes according to the cytomorphology, immunophenotype and genetic 
information of the leukemic cells (Bacher 2009). During the last decade, microarray-based 
genomic profiling (Simons 2011), fluorescence in-situ hybridization (FISH), polymerase chain 
reaction (PCR) and candidate gene sequencing or next-generation sequencing (NGS) (Bacher 
2009, Grossmann 2011, Atak 2012) have been used in the characterization of ALL. The 
characterization of the ALL subtype by using a combination of several methods is essential for 
the stratification of patients into distinct prognostic risk groups and the planning of optimal 
treatment (Grossmann 2011). 
As one example, TEL-AML1 gene fusion, which is the most common B-lineage ALL 
phenotype, has a favourable outcome, partly due to its sensitivity to L-asparaginase (Loh 2006) 
whereas infant ALL with mixed lineage leukemia (MLL) rearrangement still remains a 
challenge to therapy (Pui 2010). In Finland, approximately 60 new cases of ALL occur in 
children each year and most of them have the Pre-B-ALL subtype. Finnish laboratories use 
cytomorphology, surface antigen studies, cytogenetic techniques and PCR to determine the 
ALL subtypes of the patients. 
The outcome of pediatric ALL patients has improved significantly over past decades in the 
developed countries and currently more than 85% of children with ALL will be leukemia free at 
5 years (Pui 2012). On the contrary, the long-term disease-free survival rate among adults is 
significantly lower, only approximately 40% (Patil 2010). Some of those ALL subtypes which 
previously had a poor outcome, currently have a much better outlook. For example, the 
prognosis of ALL patients positive with Philadelphia chromosome (BCR–ABL1) has radically 
improved since the introduction of tyrosine kinase inhibitors (TKIs) in the therapy of these 
patients (Lee 2011). 
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Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults 
(Patel 2012) and its incidence will likely increase along with the aging population (Mawad 
2012). According to current knowledge, AML arises from the cooperation between two classes 
of genetic alterations that regulate self-renewal and differentiation (Pui 2011). Thus, AML is a 
heterogenous disease which can be categorized into distinct clinicopathologic subgroups on the 
basis of their molecular genetic defects (Döhner 2010, Roboz 2011). The 5-year event-free 
survival for AML in developed countries currently ranges between 49% and 63%.  
In the near future, there is a hope for further improvements in the cure rate for acute 
leukemias if the genetic basis of leukemogenesis can be characterized. Since this will help to 
understand and predict treatment failure and to provide novel markers for diagnostic testing 
and targeting of novel personalized therapies (Mullighan 2012, Pui 2012).  
2.3.5.2 Asparaginases in clinical use 
Since the 1970’s, L-asparaginase has been widely used in the treatment of ALL in combination 
with other drugs. The mechanism of its action is based on the dependence of leukemic 
lymphoblasts on extracellular L-Asn. Leukemic cells express only low levels of the asparagine 
synthetase (ASNS) gene and thus they have a very poor capability to produce their own 
asparagine supply. Thus, the presence of L-asparaginase during the intensive chemotherapy 
leads to depletion of L-Asn reservoirs and this affects the asparagine-dependent protein 
synthesis ultimately resulting in death of the leukemic cells (Iwamoto 2007, Chen 2011).  
During the last decade, L-asparaginase has been found to be effective also in the treatment of 
AML (Rubnitz 2009, Buaboonnam 2013). Currently, L-asparaginase is used in children in AML 
treatment protocol such as ELAM 02 2010. Especially the blast cells of AML subtypes M1, M4 
and M5 have been demonstrated to be sensitive to L-asparaginase due to their remarkably low 
level of ASNS (Okada 2003). Furthermore, L-asparaginase might be a key candidate drug for 
patients with myeloid/natural killer cell precursor acute leukemia (Morimoto 2010). 
There are currently three asparaginase preparations available for clinical use; native enzyme 
purified from E. coli (Elspar®, Medac), polyethylene glycol -conjugated E. coli asparaginase 
(PEG-asparaginase, pegaspargase, Oncaspar®) and native enzyme from Erwinia chrysanthemi 
(Erwinase®) which is antigenically distinct from the E. coli enzyme. Asparaginase therapy is 
generally started with native E. coli ASNase, but if this form is not tolerated, it may be changed 
to PEG-asparaginase. In UK, all children with ALL receive Oncaspar® (Patel 2009). PEG-
asparaginase has proved to be effective and requires less frequent injections than the E. coli and 
Erwinia asparaginases due to its longer half-life (Graham 2003). In case of development of 
clinical allergies to native E. coli asparaginase or PEG-asparaginase, a switch to Erwinia L-
ASNase is recommended (Raetz 2010). In Finland, PEG-asparaginase is used unless a switch to 
Erwinia asparaginase is needed due to allergic reactions.  
One promising formulation of L-asparaginase is GRASPA®, a suspension containing 
homologous human red blood cells loaded with L-asparaginase as an active component and 
SAG-mannitol as a preservative. In the blood circulation, red blood cells act like micro-size 
bioreactors pumping L-asparagine from plasma to the erythrocytes, in which the asparagine is 
cleaved by L-asparaginase. The results of the GRASPALL 2005-01 trial, a phase I/II study in 
children and adults with ALL in first relapse, showed that one single 150 iu/kg GRASPA® dose 
was as effective as eight injections of 10000 iu/m2 of native E. coli L-asparaginase. In addition, 
GRASPA® evoked fewer side effects than the native enzyme. Furthermore, the half-life of 
GRASPA® was as long as 40 days and one dose maintained the asparagine depletion for 18.5 
days (Domenech 2011). At present (the beginning of 2013) there are two studies ongoing in 
Europe with GRASPA®, a phase II/III study in relapsed and allergic ALL patients and a phase II 
clinical trial as a first line treatment in adults.  
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2.3.5.3 Side effects caused by L-asparaginase therapy 
The majority of ALL patients suffer from side-effects such as pancreatitis, thrombosis, central 
nervous system complications, liver dysfunction, allergic reactions and even severe 
anaphylactic shock during L-asparaginase therapy. Especially teenage and adult ALL patients 
are more likely to suffer from side-effects (Avramis 2006) severe enough to limit the use of high-
dose L-asparaginase therapy. Hypersensitivity is the most common toxicity caused by L-
asparaginase therapy with a frequency of up to 30% in ALL patients. The reason for 
hypersensitivity is the development of anti-asparaginase antibodies against the bacterial 
proteins foreign to the human body, which may shorten the half-life of asparaginase and 
decrease its activity. In some cases, a phenomenon called silent hypersensitivity arises when 
circulating antibodies neutralize asparaginase without causing any clinical symptoms of 
hypersensitivity (Raetz 2010).  
The toxicity of E. coli and Erwinia asparaginases is also related to their L-glutaminase activity, 
which affects the nitrogen transportation in blood and exerts biochemical disorders especially in 
liver (Ollenschläger 1988, Krasotkina 2004). If asparaginase depletes both asparagine and 
glutamine, then asparagine synthetase is not able to produce enough asparagine from aspartate 
and glutamine. Reinert and colleagues studied tissue-specific nutrient stress in mice, 
demonstrating that E. coli asparaginase abolished circulating levels of asparagine and 
glutamine, resulting in reduced protein synthesis in liver and spleen but not in pancreas. On the 
contrary, glutaminase-free asparaginase from Wolinella succinogenes did not provoke any 
changes in protein synthesis in any tissues (Reinert 2006).  
Several approaches have been tested to decrease the activity of asparaginase against 
glutamine. Engineering of substrate specificity by site-directed mutagenesis (Derst 2000) and in 
silico mutagenesis (Offman 2011) have demonstrated that glutaminase activity can be 
minimized and the corresponding asparaginase activity even increased. In addition, novel L-
asparaginase sources with negligible glutaminase activity have been identified (Kumar 2011, 
Dhavala 2009). Recently, however, it was shown by Offman that some glutaminase activity is 
required in order to maintain the optimal activity of E. coli asparaginase. Offman demonstrated 
that glutaminase activity can be reduced at least to half of the wild type activity without 
affecting the overall asparaginase activity, but a glutaminase-free asparaginase exhibited 
significantly reduced asparaginase activity. It remains to be determined whether other bacterial 
asparaginases also need some glutaminase activity in order to maintain their efficacy as 
leukemia drugs.  
2.3.5.4 Resistance to asparaginase 
The biologic half-lives of clinically used native Erwinia L-asparaginase and E. coli L-
asparaginase are rather short 0.65±0.13 days and 1.44±0.35 days, respectively, when compared 
to PEG-conjugated asparaginase which has a half-life of 5.73±3.24 days (Raetz 2010). PEGylation 
of asparaginase increases its molecular size and structural stability thus improving the plasma 
half-life and protecting the protein against proteolytic cleavage and inactivation by serum 
proteases, e.g. trypsin (Labrou 2010).  
In addition to serum proteases, it was reported quite recently by Patel and colleagues that 
two lysosomal cysteine proteases are able to degrade asparaginases in lymphoblasts, thus 
affecting the therapeutic effect of the L-asparaginases. Cathepsin B (CTSB), which is produced 
constitutively by normal and leukemic cells, was shown to be able to degrade both E. coli and 
Erwinia L-asparaginases, whereas asparaginyl endopeptidase (AEP) was able to use only E. coli 
L-asparaginase as its substrate. AEP is overexpressed principally in high-risk pre-B ALL 
patients and thereby destroys L-asparaginase activity and possibly triggers allergic reactions 
(Patel 2009).  
One theory for asparaginase resistance is the secretion of asparagine by bone marrow 
mesenchymal cells, which offer a safe microenvironment for asparagine-dependent leukemic 
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cells (Iwamoto 2007). Resistance to asparaginase can also be caused by altered expression of 
genes involved in apoptosis (Holleman 2006) and protein synthesis (Holleman 2004). 
2.3.6 Apoptosis and asparaginase 
Apoptosis, also called programmed cell-death (PCD), is a highly regulated cascade of 
biochemical and morphological events involved in the elimination of damaged or harmful cells, 
and thus in the maintenance of cell homeostasis (Sprick 2004, Elmore 2007). Apoptosis is 
launched in response to a variety of either external or internal inducers, such as ultraviolet (UV) 
light, chemotherapeutic agents or DNA damage. According to current knowledge, the apoptotic 
cascade of events follows either the mitochondrial pathway (intrinsic route) or receptor-
mediated (extrinsic) pathway.  
During apoptosis, the apoptotic cells undergo typical morphological changes such as cell 
shrinkage and pyknosis, blebbing of plasma membrane, fragmentation of the cell nucleus, and 
finally the cells break into small membrane-surrounded particles, apoptotic bodies, which are 
phagocytosed without evoking any signs of inflammation (Elmore 2007). One of the molecular 
changes in apoptotic cells is the activation of caspases, cysteine aspartate specific proteases that 
cleave aspartate residues from numerous substrates during the early stages of apoptosis. 
Another hallmark is the movement of membrane lipid phosphatidylserine from the inner to the 
outer side of the plasma membrane thus serving as a recognition marker for phagocytes.  
L-asparaginase-induced apoptosis was reported for the first time by Story and colleagues in 
1993 when that group demonstrated DNA fragmentation and morphological changes in mouse 
lymphoma (LY-TH) cells after their exposure to L-asparaginase (Story 1993). Ueno and 
colleagues studied further the biochemical events leading to the death of murine L5178Y 
leukemic cells in the presence of L-aspraginase and they found that apoptosis is associated with 
the cell cycle arrest in G1 phase (Ueno 1997). Thereafter, asparaginase has been reported to 
induce apoptosis in natural killer cells (Ando 2005) and a subset of human sarcoma cells 
(Tardito 2007). 
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3  Aims of the present study 
1. To study the effect of enzyme replacement therapy with recombinant human 
glycosylasparaginase in a mouse model of aspartylglycosaminuria. 
2. To characterize the structure of a glycoasparagine present in the urine of an AGU patient 
as well as in the tissues of the AGU mouse model.  
To determine quantitatively the amount of glycoasparagine and GlcNac-Asn in AGU 
mice tissues as well as in AGU mice treated with enzyme replacement therapy. 
3. To characterize the substrate specificities of two bacterial L-asparaginases, EcAII and 
ErAII, by utilizing β-aspartylpeptides as substrates 
4. To evaluate the ability of recombinant human glycosylasparaginase to deplete the intra- 
and extracellular Asn reservoirs in vitro using EBV transformed lymphoblasts.  
To study the ability of GA to induce apoptosis in B- and T-lineage ALL cells and 
compare its cytotoxicity to clinically used bacterial L-asparaginases, EcAII and ErAII. 
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4  Materials and methods 
4.1 REAGENTS 
The reagents used in this study have been described in detail in the original papers (I-IV). β-
Aspartylpeptides were prepared as previously described (Hanson 1964, Fastrez 1973) (III).  
4.2 HUMAN RECOMBINANT GLYCOSYLASPARAGINASE (I, II, IV) 
The recombinant human GA was stably overexpressed in NIH-3T3 mouse fibroblasts. The 
recombinant enzyme was purified with fast protein liquid chromatography (FPLC) by using gel 
filtration, DEAE-Sepharose and Mono-Q anion exchange columns as described previously by 
Kaartinen and colleagues (Kaartinen 1991). In the enzyme replacement therapy in the AGU 
mouse model, the enzyme was dialyzed into injection buffer containing 150 mM NaCl, 10 mM 
Tris-HCl and 1 mM β-glycerophosphate, pH 7,5 (I, II). 
Dephosphorylation of recombinant GA (4.4 U) was carried out at 37 °C for 3.5 h in the 
presence of 1.6 U of alkaline phosphatase (ALP) in 50 mM Tris-HCl, pH 8, in a total volume of 1 
ml. After incubation, the dephosphorylated GA was dialysed into phosphate buffered saline 
(PBS) and then sterile filtered. The final activity of the sterile dephosphorylated stock GA 
preparation was 6780 U/l.  
 
4.3 CELL LINES 
Mouse NIH-3T3 fibroblasts cultured in Dulbecco’s Modified Eagle Medium (DMEM) and 
supplemented with 10% fetal calf serum (FCS) were used for the production of recombinant 
human GA (Mononen 1995) (I, II, IV). 
Epstain Barr virus (EBV) -transformed GA-deficient lymphocytes were established as 
described (Volkman 1984) and cultured in RPMI-1640 supplemented with 15% FBS, 71 mg/ml 
streptomycin, 71 U/ml penicillin, and 2 mM L-glutamine. Those cells were used to study the 
ability of recombinant GA to deplete L-asparagine reservoirs in the cell culture medium as well 
as inside the cells (IV).  
SUP-B15 cells established from the bone marrow of a 9-year-old boy with acute 
lymphoblastic leukemia (B cell precursor ALL) carrying the ALL-variant (m-bcr) of the BCR-
ABL fusion gene (e1-a2) were bought from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (DSMZ, Braunschweig, Germany) and those cells were used in the 
cytotoxicity and apoptosis assays. Human T-lineage ALL CCRF-CEM cells established from the 
peripheral blood of a 3-year-old Caucasian girl with acute lymphoblastic leukemia (ALL) were 
from DSMZ (Braunschweig, Germany) (IV) and they were used in the cytotoxicity assays. 
 
4.4 MOUSE MODEL OF ASPARTYLGLYCOSAMINURIA 
The mouse model of AGU was generated as described elsewhere (Kaartinen 1996). The AGU 
mice in the enzyme replacement therapy experiments were aged from 9 months to 19 months (I, 
i.v. injections) or over one year (II, i.p. injections). In addition, 3- or 6-week-old AGU mice were 
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used to follow the effect of age on the accumulation of two glycoasparagines, GlcNAc-Asn and 
Man2GlcNAc2-Asn, in mouse tissues (II). In the analysis of GlcNac-Asn and Man2GlcNAc2-Asn 
in mouse tissues, the animals were anesthetized and then intracardially perfused with 0.9% 
NaCl (I, II). The collected tissues were stored at -70 °C until thawing and homogenization. 
Tissues were homogenized on ice in 50 mM Na-K-phosphate buffer, pH 7.5, containing 0.1 % 
Triton X-100 and then lysed by three freezing and thawing cycles and sonication.  
 
4.5 ASSAY METHODS 
4.5.1 Determination of L-Asn (IV), GlcNAc-Asn (I, II) and Man2GlcNAc2-Asn (II) 
The concentrations of Man2GlcNAc2-Asn and GlcNAc-Asn as their phenylisothiocyanate (PITC) 
derivatives in tissues and urine, as well as the L-Asn level in the cell culture medium and inside 
the GA-deficient lymphoblasts were assayed by HPLC by using a Merck/Hitachi L-6200 liquid 
chromatograph (Hitachi Ltd., Tokyo, Japan) as described (Kaartinen 1990). CmCys was used as 
the internal standard. 
The structure of Man2GlcNAc2-Asn in AGU mouse tissues was confirmed by sequential 
digestion by exoglycosidases α(1-6)-mannosidase, β-mannosidase and β-N-
acetylglucosaminidase. The quantitative analysis of the degradation products as their 9-
fluorenylmethyl chloroformate (FMOC) derivatives was performed by HPLC using CmCys as 
the internal standard (II).  
4.5.2 Determination of GA activity (I, II, IV) 
The activity of purified GA preparate (I, II, IV) and its activity in the cell lysates (IV) were 
determined by a fluorometric method (Mononen 1993) using β-(7-amido-4-methylcoumarin)-L-
aspartic acid as a substrate. One unit of enzyme hydrolyzes 1 μmol of substrate per minute 
under standard conditions. GA activity in tissue homogenates was analyzed by HPLC as 
described (Kaartinen 1990) using CmCys as the internal standard.  
4.5.3 Protein concentration 
Protein concentrations of tissue homogenates, cell lysates and purified enzyme preparations 
were determined by using a Bio-Rad protein assay kit according to the manufacturer’s 
instructions. 
4.5.4 Enzyme kinetics of L-asparaginases using β-aspartylpeptides as substrates (III) 
Determination of kinetic parameters of L-asparaginases by using β-aspartylpeptides as 
substrates was performed at 23 °C with a spectrophotometric assay (Tarentino 1969). Briefly, 
various substrate concentrations were incubated in microplate wells in the presence of NADH, 
MDH and ASAT for 15 minutes. Then, either E. coli L-asparaginase (Elspar®) or Erwinia L-
asparaginase (Erwinase®) was added to achieve a final L-asparaginase activity of 91 U/l. Blank 
wells were incubated without enzyme and the blank values were subtracted from the actual 
measurements. The rate of the absorbance decrease at 340 nm was followed with a Tecan 
SpectraFLUOR spectrophotometer, Tecan Austria GmbH, Grödig, Austria, and the kinetic 
parameters were calculated using the Enzpack for Windows, version 1.4, Biosoft software 
package. 
4.5.5 The cytotoxicity assay (IV) 
The Cell Proliferation Kit I (MTT) Boehringer Mannheim GmbH (Mannheim, Germany) was 
used to determine the IC50 values for recombinant GA, dephosphorylated GA, E. coli L-
asparaginase (Elspar®) and Erwinia L-asparaginase (Erwinase®) in CCRF-CEM and SUP-B15 
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leukemia cell culture. Shortly, various concentrations of the enzymes were incubated at 37 °C in 
microtiter plate wells in the presence of either SUP-B15 or CCRF-CEM cell suspension, and after 
three (SUP-B15) or four (CCRF-CEM) days of culture, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) reagent was added into each well. After another 4 hours, the 
solubilization reagent was added to wells and the plate was incubated overnight at 37 °C. 
Finally, the absorbance of the wells at 540 nm was measured by using a Tecan SpectraFLUOR 
spectrophotometer, Tecan Austria GmbH (Grödig, Austria). ORIGINTM Data Analysis Software, 
Microcal Software Inc., (MA, USA) was used to plot the dose-response curves. 
4.5.6 Assay of apoptosis (IV) 
In Situ Cell Death Detection Kit, TMR red (Boehringer Mannheim GmbH, Mannheim, 
Germany), which is based on the TdT-mediated dUTP nick-end labelling (TUNEL) method, was 
used to detect apoptosis both at the single cell level and in a cell population. SUP-B15 cells were 
incubated for two days in the presence of either recombinant GA, dephosphorylated GA 
(Elspar®) or Erwinia L-asparaginase (Erwinase®). After fixation and permeabilization, the cells 
were stained with tetramethylrhodamine (TMR) and 4’,6-diamidino-2-phenylindole (DAPI), 
and the apoptotic (TMR, red) cells in the total cell population (DAPI, blue) were detected with a 
ZEISS Axioplan 2 imaging microscopy (Jena, Germany) and Isis in situ-imaging system 
software, MetaSystems GmbH (Altlussheim, Germany). Secondly, to determine the proportion 
of apoptotic cells in the whole cell population, the SUP-B15 cells were incubated in the presence 
of PBS (negative control), dephosphorylated GA or ErAII (positive control) for two days and 
after fixation and permeabilization the cells were stained with TMR. The cells were analyzed 
with a Coulter EPICS XL-MCLTM Flow Cytometer, Coulter Corporation (Miami, Florida, USA) 
and EXPOTM Analysis Software, Applied Cytometry Systems (Sheffield, UK). 
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5  Results 
5.1 ENZYME REPLACEMENT THERAPY WITH RECOMBINANT HUMAN 
GLYCOSYLASPARAGINASE IN THE MOUSE MODEL OF AGU (I) 
The level of GlcNAc-Asn accumulation was determined quantitatively in untreated AGU mice, 
wild type mice and in AGU mice treated with GA. It was shown that a single intravenous GA 
dose, 1 mg/kg, reduced the GlcNAc-Asn concentration by 94% in liver and 82% in spleen of the 
treated adult AGU mice. In heart, jejunum, kidney and heart the respective values were 16%, 
54%, 17% and 29%. A single intravenous dose did not reduce the GlcNac-Asn concentration in 
brain tissue. An injection of 8 x 1 mg/kg of GA reduced the GlcNAc-Asn storage by 60-100% in 
the non-neuronal tissues of the treated AGU mice, but in brain tissue the accumulation 
remained unchanged. After eight injections of the GA at a dose of 10 mg/kg, GlcNAc-Asn was 
totally cleared from liver, spleen, kidney, heart and jejunum, and in brain tissue its 
accumulation was reduced by 20%. 
After the GA treatment, the GA activity in the liver and spleen was dose-dependent – the 
higher the dose, the greater the GA activity. A single 1 mg/kg injection raised the activity in 
liver to 45% and in spleen to 21% of that of untreated wild-type mice, but in other tissues 
enzyme activity remained low or undetectable. After eight 1 mg/kg doses, the GA activity in 
liver and spleen was comparable to that of the untreated wild-type mice, but it remained 
unchanged in the other tissues. On the contrary, a marked increase in GA activity was detected 
in all non-neuronal tissues of adult AGU mice after the treatment protocol with 8 x 10 mg/kg. 
The highest GA activity was found in liver and spleen tissues, in which the activity was 87-fold 
and 67–fold higher than the corresponding value of untreated adult AGU mice. In the brain 
tissue, the activity of GA was 10% of that of wild-type mice.  
The mean urinary excretion of GlcNAc-Asn of adult untreated AGU mice was 256 
μmol/mmol creatinine (range 204-307 μmol/mmol creatinine). The ERT with either 1 mg/kg or 
10 mg/kg intravenous dose every second day for 15 days reduced the excretion level of GlcNAc-
Asn by 60% and 90% by the end of the therapy, respectively.  
Examination of AGU mouse tissues by light and electron microscopy after the ERT with 8 x 
10 mg/kg every second day revealed an effective correction of tissue pathology in the spleens 
and kidneys of treated AGU mice, whereas in their liver tissue, the vacuolization was not so 
clearly absent. Immunostaining with GA antibodies showed a wide distribution of the enzyme 
especially in the sinusoidal lining cells of the liver tissue as well as in the lymphoid cells and 
macrophages in the red pulp of the spleen of the treated AGU mice. 
Plasma clearance of GA was found to be a two-phased process. The first rapid decline in 
serum GA activity, with a t1/2 of 4 min, was followed by a slower phase with a half-life of 39 min. 
During the first phase, the enzyme had probably distributed within the vascular space or 
extracellular fluids, and during the slower phase it passed into tissues. 
 
5.2 ACCUMULATION OF MAN2GLCNAC2-ASN IN AGU MOUSE TISSUES AND 
THE EFFECT OF ENZYME REPLACEMENT THERAPY WITH HUMAN 
RECOMBINANT GLYCOSYLASPARAGINASE (II) 
5.2.1 Characterization of a glycoasparagine 
In addition to GlcNac-Asn, AGU mouse tissues – especially liver - and urine showed massive 
accumulation of another compound by HPLC analysis. It was demonstrated by HPLC that the 
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compound was also not hydrolyzed by neuraminidase, α-fucosidase, β-galactosidase, β-
mannosidase, β-N-acetylglucosaminidase nor Erwinia asparaginase (Erwinase®). On the 
contrary, the presence of α-mannosidase totally cleared the Man2GlcNAc2-Asn peak and the 
ManGlcNAc2-Asn was formed. After the addition of β-mannosidase into the reaction mixture, 
ManGlcNAc2-Asn was hydrolyzed to GlcNAc2-Asn and finally after the incubation with β-N-
acetylglucosaminidase only the GlcNAc-Asn peak was shown. It was demonstrated that the 
terminal mannose was not hydrolyzed by α(1-2)(1-3) mannosidase, but in the presence of α(1-6) 
mannosidase, it was rapidly cleared. In conclusion, the storage compound present in AGU 
mouse tissues and urine, as well as in AGU patient’s urine, was characterized as a 
glycoasparagine carrying the tetrasaccharide moiety of α-D-Man-(1Æ6)-β-D-Man-(1Æ4)-β-D-
GlcNAc-(1Æ4)-β-D-GlcNAc-(1ÆN)-Asn (Man2GlcNAc2-Asn, Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Structure of Man2GlcNAc2-Asn, and its hydrolysis by α(1-6)mannosidase, β-mannosidase, 
β-N-acetylglucosaminidase and glycosylasparaginase 
 
5.2.2 Hydrolysis of Man2GlcNAc2-Asn by recombinant glycosylasparaginase 
When an aliquot of AGU mouse liver tissue was incubated in the presence of GA both 
glycoasparagines, Man2GlcNAc2-Asn and GlcNAc-Asn, were hydrolyzed totally in 5 h (Fig 11). 
The reaction velocity of Man2GlcNAc2-Asn was 32,5 μM/min and that of GlcNac-Asn 34,4 
μM/min. 
Figure 11. Hydrolysis of Man2GlcNAc2-Asn (○) and GlcNAc-Asn (□) in the presence of 
glycosylasparaginase (9.1 U/L) in AGU mouse liver extract 
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5.2.3 Man2GlcNAc2-Asn and GlcNAc-Asn in AGU mouse tissues 
The most massive accumulation of Man2GlcNAc2-Asn was found in liver and spleen of adult 
AGU mice being 87% and 57% of the corresponding GlcNAc-Asn values. In other non-neuronal 
tissues of adult AGU mice, the level of Man2GlcNAc2-Asn was 28-76% of that of GlcNAc-Asn, 
whereas in brain, it was only one tenth of that of GlcNAc-Asn (Fig. 12). In liver and spleen, the 
concentration of Man2GlcNAc2-Asn increased with the age of the mice, whereas the GlcNAc-
Asn accumulation in those tissues remained at the same level during the age period from 3 
weeks to over one year. This type of age-dependence of the glycoasparagine storage was not 
found in other tissues. 
 
 
Figure 12. Accumulation of Man2GlcNAc2-Asn (white columns) and GlcNAc-Asn (grey columns) in 
adult AGU mouse tissues 
5.2.4 Effect of ERT 
After 13 intraperitoneal injections of GA, the activity of GA was found to be in the wild-type 
range in the liver of the treated AGU mice whereas in heart and lung enzyme activity was only 
1% of that measured in the wild-type mice. The highest GA activity in the treated AGU mice 
was found in spleen, in which the activity was fourfold higher than in corresponding wild-type 
tissue. The therapy protocol effectively cleared the accumulation of both Man2GlcNAc2-Asn and 
GlcNAc-Asn from non-neuronal tissues of adult AGU mice by 55-98%, but less effectively, by 
13-21%, from brain (see Table 8). Enzyme therapy with GA reduced the mean excretion of 
Man2GlcNAc2-Asn into the urine of adult AGU mouse by 72% and that of GlcNAc-Asn by 84%. 
 
Table 8. Effect of ERT with GA on tissues of AGU mice 
  
[GlcNAc-Asn] % of 
KO 
[MMGGA] % of 
KO 
GA activity  
% of WT 
Liver 2 3 84 
Spleen 6 10 392 
Kidney 29 21 0 
Lung 33 34 2 
Heart 45 8 1 
Brain 79 87 0 
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5.3 HYDROLYSIS OF Β-ASPARTYLPEPTIDES BY BACTERIAL L-
ASPARAGINASES (III) 
Two bacterial L-asparaginases derived from E. coli (Elspar®, EcAII) and Erwinia chrysanthemi 
(Erwinase®, ErAII) were capable of catalyzing the hydrolysis of several β-aspartylpeptides, 
particularly small size β-aspartyl amino acid amides. β-aspartylserineamide was hydrolyzed at 
half of the rate of L-Asn and β-aspartylalanamine or β-aspartylglycineamide had relative 
hydrolysis rates of 1/10-1/50 of that of Asn, respectively. The substrate specificity of the two 
bacterial L-asparaginases was rather similar with two exceptions: ErAII catalyzed the 
hydrolysis of H-Asp((Gly)4-OH))-OH, but it was not hydrolyzed by EcAII, and secondly, EcAII 
could hydrolyze H-Asp(Phe-OMe)-OH, but this peptide remained unhydrolyzed by ErAII. 
These experiments were performed at 23 °C although in the human body at 37 °C the Vmax may 
be even higher. 
5.4 INDUCTION OF APOPTOSIS IN HUMAN T- AND B-LINEAGE ACUTE 
LYMPHOBLASTIC LEUKEMIA CELLS IN VITRO BY GLYCOSYLASPARAGINASE 
(IV) 
Glycosylasparaginase was able to deplete both intra- and extracellular reservoirs of L-
asparagine in the EBV-transformed GA-deficient lymphoblast culture. Hydrolysis of L-Asn 
from 2.3 to 0.2 mmol/l in the cell culture medium required a period of 4 hours in the presence of 
either 40 U/l GA or 10 U/l Erwinia L-asparaginase (Erwinase®). With lower GA activity, 10 U/l, 
the hydrolysis rate was remarkably slower and the Asn concentration of 0.2 mmol/l was not 
reached before 18 hours of incubation.  
Intracellular Asn reservoirs of lymphoblasts were cleared in a dose-dependent manner – the 
higher the enzyme activity, the faster the hydrolysis. The highest Erwinase® activity, 1500 U/l 
cleared the Asn within one minute, but in the presence of enzyme doses 10 or 40 U/l of GA and 
10 U/l of Erwinase®, the Asn concentration inside the cells initially increased during the first 
two hours of incubation and then gradually decreased to one tenth of the control cells within 
the next 6-18 hours. The enzyme activity inside the cells reached its peak in 1-2 hours and then 
gradually decreased within the next 24 hours. 
GA induced cell death in two leukemic cell lines, human B cell precursor leukemia SUP-B15 
cells and human T-lineage ALL CCRF-CEM cells, with similar efficacy than two bacterial L-
asparaginases, Elspar® (EcAII) and Erwinase® (ErAII), which are routinely used in the treatment 
of ALL. The dephosphorylation of GA with alkaline phosphatase to prevent its transportation 
into cells did not affect its antileukemic efficacy; on the contrary, dephosphorylated GA was 
slightly more effective in killing the T-lineage ALL CCRF-CEM cells.  
B-lineage ALL cell line SUP-B15 was 130-650 –fold more sensitive to all of the tested enzymes 
than T-lineage ALL CCRF-CEM  cells, which was consistent with previous studies 
demonstrating the resistance of CCRF-CEM cells to L-asparaginase. The cytotoxicity of 
recombinant GA, dephosphorylated GA, ErAII and EcAII in B-lineage SUP-B15 ALL cell line 
was found to be rather similar. The IC50 value of each enzyme is listed in Table 9. The most 
effective enzyme in killing of SUP-B15 cells was EcAII which displayed an IC50 value of 4 U/l. 
The corresponding median IC50 values of ErAII, recombinant GA and dephosphorylated GA 
were 6 U/l, 12 U/l and 16 U/l, indicating that GA possesses significant cytotoxic activity of the 
same order of magnitude as the bacterial L-asparaginases used in ALL therapy. With an 
enzyme dose of 1000 U/l, ErAII killed 52% of the CCRF-CEM cells, whereas the corresponding 
dose of dephosphorylated GA, GA and EcAII killed 40%, 30% and 43% of the cells. 
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Table 9. The cytotoxicity of GA, dephosphorylated GA, ErAII and EcAII in SUP-B15 cells in vitro. IC50 
value indicates that enzyme concentration required to induce death of half of the cell population. 
 
Enzyme IC50 value (U/l) 
GA 12 
Dephosphorylated GA 16 
ErAII (Erwinase®) 6 
EcAII (Elspar®) 4 
 
Most of the SUP-B15 cells were apoptotic and displayed a red colour when incubated for two 
days at 37 °C in the presence of 100 U/l of dephosphorylated GA and stained with TMR and 
DAPI (Fig. 13 ). The proportion of apoptotic cells in the SUP-B15 cell population in the presence 
of either 100 U/l of dephosphorylated GA or 1,000,000 U/l ErAII was 65% and 69%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. SUP-B15 cell population visualized under a fluorescence microscope with DAPI (blue, 
showing all the cells) and TMR (red, showing apoptotic cells) 
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6  Discussion 
6.1 EFFECT OF ENZYME REPLACEMENT THERAPY IN AGU MOUSE MODEL 
In recent decades, remarkable progress has been achieved in the enzyme replacement therapy 
of lysosomal storage diseases. However, the presence of BBB, which protects the CNS by 
selectively regulating the transport of molecules from the blood circulation into the CNS or vice 
versa (Fu 2011), complicates the development of treatment protocols for neurodegenerative 
LSDs. When this study was launched, enzyme therapy had been successful only in the non-
neuronal tissues of LSD animal models and patients. Similarly, ERT with AGU had only been 
shown to be effective in cell cultures. As soon as the mouse model of AGU became available, it 
quickly proved to be a valuable tool for studying the effects of enzyme therapy on different 
tissues, also in brain.  
In the first part of this work, intravenously administered recombinant GA at a high dose not 
only reached the non-neuronal tissues of the adult AGU mice, but also the brain. The increase in 
GA activity corresponding to 10% of the wild type activity led to a 20% decrease in GlcNAc-Asn 
concentration in the brain tissue. Furthermore, there was a complete clearance of GlcNAc-Asn 
from the liver, heart, kidney, jejunum, and spleen tissues. The results were better than expected 
in relation to the high age of the treated AGU mice.  
The mechanism by which the high-dose enzyme is able to cross BBB of adult mice is still not 
known and the possible explanations are merely speculations. For example, it has been 
postulated that the enzyme may be taken up micropinocytosis or by other receptors than the 
MPRs (Blanz 2008), or there might be extracellular pathways that allow small amounts of large 
molecules to enter the CNS (Vogler 2005). One possible reason why some lysosomal enzymes 
can be delivered through the BBB whereas other large molecules are excluded may be due to 
the differences in the mode of uptake (Rozaklis 2011). GA is transported into AGU 
lymphoblasts and fibroblasts through mannose-6-phosphate mediated endocytosis (Dunder 
2010) suggesting that there might be a specific M6P receptor responsible for GA delivery 
through BBB in AGU. 
Recent studies with neurodegenerative LSDs have shown that it might be possible to 
overcome the BBB, at least to some extent. For example, ERT with the recombinant human α-
mannosidase (rhLAMAN) in adult α-mannosidosis mice (Blanz 2008) was able to reach the CNS 
as high doses and successfully clear the accumulated substrate behind the BBB leading to a 
complete reversal of ataxic symptoms. However, the therapy did not significantly improve the 
neurocognitive and exploratory defects in these mice, probably due to the short duration of the 
experiment. Moreover, high-dose ERT proved to be effective in murine mucopolysaccharidosis 
VII brain using recombinant human β-glucuronidase (hGUS) (Vogler 2005). 
In addition to the enzyme dose, the initiation of ERT at an early age is crucial for the 
successful therapy. For example, more recent ERT study with newborn AGU mice showed a 
twofold more effective clearance of the accumulated GlcNAc-Asn from the brain tissue than 
ERT in adult AGU mice (Dunder 2010). Interestingly, BBB of young mice was permeable to 
AGA even though the enzyme was administered intraperitoneally, although the i.p. route was 
not as effective as i.v. therapy. Access of enzyme through BBB of newborn mice was also 
studied with MPS IIIA by Gliddon and Hopwood, and according to their results, ERT with 
recombinant human sulfamidase is able to delay the development of behavior and learning 
difficulties in MPS IIIA mice if the therapy is started before the BBB maturation (Gliddon 2004). 
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ERT studies with other glycoproteinoses than AGU have shown variable results. For 
example, the treatment of sialidosis mice with recombinant neuraminidase (Neu1) evoked a 
significant reduction of lysosomal storage in systemic organs, but no improvement was 
detected in brain tissue. In addition, the treated mice developed a severe immune response 
towards the exogenous enzyme (Wang 2005). A similar trend was observed in the mouse model 
of galactosialidosis treated with Baculovirus-expressed protective protein/cathepsin A (PPCA) 
and neuraminidase (Neu1) (Bonten 2004).  
Future alternatives to enable more significant access through BBB may benefit from the 
chemical modification of the therapeutic enzyme. For example, Grubb et al. tested the feasibility 
of ERT in MPS VII mice with sodium meta-periodate-oxidized β-glucuronidase (GUS); they 
demonstrated that the enzyme was successfully transported across the BBB thus correcting the 
storage in deficit neurons (Grubb 2010). In addition to its better uptake to brain tissue, the half-
life of the modified enzyme in blood was remarkably prolonged. The modification of the 
enzymes reduces their clearance rate by liver and spleen and thus enables less frequent 
injections of the enzyme. Another ERT study with periodate-treated enzyme was performed by 
Rozaklis et al. by using chemically modified recombinant human sulfamidase (rhSGSH) in the 
MPS IIIA mouse model. It was found that periodate-treated enzyme could reach the brain tissue 
of MPS IIIA mice but it was unable to reduce the relative level of the accumulated substrates in 
brain cells. However, a modification of rhSGSH significantly improved the clearance of GlcNS-
UA in non-neuronal tissues potentially due to its longer half-life in plasma (Rozaklis 2011). 
It was demonstrated that the half life of the GA in serum was about 4 min in the first rapid 
phase followed by a half-life of 39 min during the slower phase. In liver tissue of AGU mice, the 
half-life of GA has been shown to be two days (Tollersrud 1988). There are potential techniques 
available to increase its half life; the enzyme could be covalently coupled to PEG or 
encapsulated inside red blood cells (Domenech 2011). Furthermore, the structure of GA could 
probably be tailored to achieve resistance to trypsin cleavage (Kotzia 2007) or to prevent the 
inactivation by lysosomal proteases Cathepsin B (Offman 2011) using similar techniques as 
used for bacterial asparaginases.  
One interesting alternative to overcome the BBB of adults is to use epinephrine stimulation. 
Urayama and the colleagues found that transport of the enzyme P-GUS across the BBB could be 
induced in adult MPS VII mice by treating them with epinephrine and that this transport was 
attributable to the M6P receptor, the same receptor responsible for P-GUS transport in the 
neonate (Urayama 2007). 
Before ERT can be made available for patients, even if the therapy seems to be effective in an 
animal model, much effort is needed to transfer the concept from the laboratory into the clinic. 
There exist many stages on the route from an idea to the ultimate approval and registration of 
the treatment. After the demonstration of clinical improvement in an animal model and 
availability of sufficient amounts of the therapeutic enzyme, scale-up of the therapeutic for 
human use as well as phase I, II and III clinical trials are needed (Hemsley 2011). The costs 
involved in this process are enormous and usually require funding by government and 
different societies and the participation of the pharmaceutical industry. It will be challenging to 
find a solution to the problem of developing cost-effective ERT. The currently used therapy 
protocols require frequent injections of expensive enzyme at relatively high-doses. Perhaps the 
chemical modification of the enzymes would translate into lower doses and less frequent 
injections of enzymes. There do seem to be ways to overcome the BBB since promising results 
have been achieved by direct injection of the therapeutic enzyme into cerebrospinal fluid. This 
therapeutic approach is currently in clinical trials with MPSI and MPS IIIA, yet it remains to be 
clarified which dosage schedule and injection route will provide the best results. In addition, 
gene therapy is a promising approach for the treatment of LSDs, because currently there are 
virus vectors available able to cross the BBB, as confirmed with MPS IIIB mice (Hawkins-
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Salsbury 2011). Combination therapy may be more effective than a single therapy. However, 
every LSD is different and thus the optimal combination has to be found for each disease.  
At present, there are no clinical trials investigating the efficacy of ERT ongoing for 
neurodegenerative LSDs but human trials are planned for α-mannosidosis. The therapy of 
every LSD should be started as soon as possible before irreversible damage has occurred. Thus, 
newborn screening is important in order to make the correct diagnosis as early as possible. 
In the light of the present results and the most recent ERT studies with AGU mice, enzyme 
replacement therapy with GA may be beneficial and the therapy should be started as soon as 
possible before the newborn’s BBB is fully mature. In addition, the optimization of the GA 
dosage and the frequency of the administrations may reduce the storage of GlcNAc-Asn more 
effectively in brain tissue, thus improving also the cognitive impairment. The promising results 
with the modification of therapeutic enzymes suggest that also the half-life of GA may be 
prolonged. 
6.2 GLYCOPROTEIN MAN2GLCNAC2-ASN IN AGU MOUSE TISSUES 
In this study, a closer look was taken to a glycoprotein present in AGU mouse tissues and urine. 
The structure of the glycoprotein was confirmed as Man2GlcNAc2-Asn (MMGGA) and it was 
found at concentrations as high as 30–87% of those of GlcNac-Asn, in non-neuronal tissues of 
untreated AGU mice. MMGGA fragments have also been found in the liver, spleen, kidney, 
thyroid and brain of AGU patients (Gordon 1998, Maury 1980) albeit their quantitative amounts 
in tissues have not been studied. One possible reason for the accumulation of MMGGA is that 
the α-(1-6)-linked mannose of the pentasaccharide core unit in Asn-linked glycoproteins cannot 
be hydrolyzed by α(1-6) mannosidase before removal of Asn by GlcNac-Asn, as demonstrated 
by Haeuw (Haeuw 1994).  
The accumulation of MMGGA in the liver and spleen of the untreated AGU mice increased 
with the age of the mice. The probable reason for the age-dependent storage may be disturbed 
function of chitobiase in the presence of high amounts of GlcNAc-Asn and MMGGA in the 
lysosomal milieu. In contrast to GlcNAc-Asn, the amount of MMGGA in brain tissue was 
insignificant, only one tenth of GlcNAc-Asn, suggesting that it has only a minor role in the 
central neuronal system symptoms encountered in AGU. The reason for the low MMGGA 
concentration in brain tissue might be due to the ability of the major lysosomal mannosidase to 
hydrolyze α(1-6)-mannose (Aronson 1999). In addition, it has been suggested that chitobiase 
activity is higher in brain than in liver (Fisher 1992). Furthermore, there might be alternative 
degradation pathways present in brain.  
ERT delivered via 13 intraperitoneal injections of recombinant GA effectively cleared 
MMGGA as well as GlcNAc-Asn from the non-neuronal tissues in amounts ranging from 55% 
to 98%. The highest GA activity was found in liver and spleen of the treated AGU mice whereas 
in heart and lung, the activity was negligible. It has been also demonstrated with other LSD 
animal models that there is variation in the uptake of the enzymes into different tissues. These 
differences have been attributed to the enzyme itself as well as its level of phophorylation and 
glycosylation (Roces 2004). The degradation rate of MMGGA in liver tissue extract of an AGU 
mouse was 94% of that of GlcNac-Asn. This result is in line with the kinetic spectrophotometric 
analysis conducted by Kaartinen et al. (Kaartinen 1992) which calculated a relative rate 85% of 
that of GlcNAc-Asn for high mannose type glycoasparagine Man6GlcNac2-Asn. After receiving 
13 i.p. injections of recombinant GA, the excretion of MMGGA into urine of AGU mice was 
reduced by 72% and that of GlcNac-Asn by 84%. The urinary excretion of MMGGA and 
GlcNAc-Asn was not corrected to the normal level even with the highest enzyme dosage, 
indicating that these compounds continue to leak into the systemic circulation from the tissues 
that are not accessible to the glycosylasparaginase. 
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The accumulation of GlcNAc-Asn in AGU patients’ tissues and body fluids is considered to 
be the main reason for clinical symptoms of the disease, but the present results suggest that the 
massive accumulation of large glycoproteins, including MMGGA, may well have also a 
significant role in the progressive pathogenesis of AGU. 
 
6.3 ENZYMATIC PROPERTIES OF HUMAN RECOMBINANT 
GLYCOSYLASPARAGINASE AND BACTERIAL L-ASPARAGINASES 
 
Glycosylasparaginase and L-asparaginase share both structural and biochemical properties, 
such as a polymeric subunit structure and the ability to hydrolyze L-asparagine to L-aspartic 
acid. Bacterial E. coli and Erwinia chrysanthemi L-asparaginases were capable of catalyzing 
especially the hydrolysis of small size β-aspartyl amino acid amides β-aspartylserineamide, β-
aspartylalanamine and β-aspartylglycineamide. Similarly to GA, bacterial asparaginases can 
hydrolyze β-aspartylserineamide at a relatively higher rate than they can break down other β-
aspartylpeptides. All of the tested β-aspartylpeptides were shown to be hydrolyzed by GA, but 
three of them were not hydrolyzed at all by the asparaginases. In addition, the relative 
hydrolysis rates of H-Asp(Gly-OH)-OH, H-Asp(Phe-OMe)-OH and H-Asp((Gly)4-OH))-OH 
were negligible when compared to those of GA (see Table 10). 
Table 10. Relative hydrolysis rates of E. coli asparaginase (EcAII), Erwinia asparaginase (ErAII) and 
glycosylasparaginase (GA) against β-aspartylpeptides 
 Relative rate (%) 
Compound EcAII ErAII GAa 
H-Asn-OH 100 100 41 
H-Asp(Ser-NH2)-OH 52 53 71 
H-Asp(Ala-NH2)-OH 8,2 8,6 35 
H-Asp(Gly-NH2)-OH 2,2 2,1 15 
H-Asp(Gly-OH)-OH 0,3 0,1 3 
H-Asp(Phe-OMe)-OH 0,2 0 23 
H-Asp((Gly)4-OH))-OH 0 0,3 8 
H-Asp(Gly-Gln-OH)-OH 0 0 27 
H-Asp(Gly-Val-OH)-OH 0 0 49 
H-Asp(GlcNAcNH)-OH 0 0 100 
aRelative rates for GA have been determined by Noronkoski et 
al. 1998. 
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The reason why GA is able to hydrolyze a wider range of β-aspartylpeptides than L-
asparaginase is most probably due to the difference in the binding site. GA has more a spacious 
active site, placing the L-asparagine part of the substrate into a narrow pocket and allowing 
variable-sized parts, such as the oligosaccharides, to extend outwards (Wang 2007). Bacterial 
asparaginases will not accommodate substrates significantly larger than glutamine as active site 
ligands (Aghaiypour 2001). In the plant-type asparaginases, access of too long molecules, such 
as L-glutamine, is prevented by the arginine side chain, which controls the length and exact 
positioning of a substrate in the active site (Michalska 2006). 
The present results suggest that the high doses of L-asparaginase used in the treatment of 
ALL could hydrolyze the β-aspartylpeptides present in human body thus causing some of the 
side effects. 
6.4 ANTILEUKEMIC CHARACTERISTICS OF GA IN VITRO 
The glutaminase activity of clinically used bacterial L-asparaginases has been linked to their 
therapeutic toxicity. Glycosylasparaginase, which is able to hydrolyse asparaginase without 
affecting glutamine metabolism, was tested in this study as a potential antileukemic drug in 
vitro. At first, GA was shown to deplete both the intra- and extracellular Asn reservoirs in vitro 
using EBV transformed GA-deficient lymphoblasts. Thus, GA fulfills the demand of an 
antileukemic drug to minimize especially the extracellular L-Asn concentration. As a result, 
those leukemic cells which lack asparagine synthase and require an exogenous source of 
asparagine for protein synthesis cannot survive.  
Furthermore, it was demonstrated that dephosphorylated GA shows similar cytotoxicity 
against the B-lineage leukemic cell line SUP-B15 when compared to bacterial asparaginases and 
native phosphorylated GA. In addition, a dose-dependent growth inhibition could be 
demonstrated in human T cell leukemia CCRF-CEM cells in vitro, but it was less effective in the 
presence of dephosphorylated GA or phosphorylated GA than the bacterial asparaginases. 
Finally, both dephosphorylated and phosphorylated GA were shown to induce the key feature 
of apoptosis, DNA fragmentation, in SUP-B15 cells.  
In conclusion, due to the comparable antileukemic characteristics of dephosphorylated GA, 
phosphorylated GA and bacterial L-asparaginases in vitro, GA might have potential as an 
anticancer-drug. In addition, GA as an endogenous human protein, might cause less side effects 
than the bacterial asparaginases. It is recommended that a further investigation using human 
leukemia xenograft mouse models could help clarify the antileukemic efficacy, 
pharmacokinetics and pharmacodynamics of glycosylasparaginase therapy in vivo. 
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presence of dephosphorylated GA or phosphorylated GA than the bacterial asparaginases. 
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In conclusion, due to the comparable antileukemic characteristics of dephosphorylated GA, 
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7  Conclusions 
The aim of this thesis was to investigate the effects of enzyme replacement therapy with 
human recombinant glycosylasparaginase on the mouse model of AGU. A further goal was to 
study the substrate specificity of bacterial L-asparaginases by using β-aspartylpeptides as 
substrates. The final goal was to evaluate the antileukaemic properties of recombinant 
glycosylasparaginase by studying its cytotoxicity in comparison with two bacterial L-
asparaginases in two ALL cell lines in vitro. The following conclusions of the thesis work can be 
drawn: 
1. This is the first time that enzyme replacement therapy with human recombinant 
glycosylasparaginase was tested in a mouse model of AGU. It was found that GA effectively 
corrected the GlcNAc-Asn storage in non-neuronal tissues of adult AGU mice, and its activity 
reached also the brain tissue. The disappearance of intravenously administered GA from the 
systemic circulation was found to be two-phased, the first phase having a t 1/2 of 4 min followed 
by a slower phase with a t1/2 of 39 min.  
2. The structure of a glycoasparagine, Man2GlcNAc2-Asn, was characterized and its massive 
accumulation was quantitatively determined in the non-neuronal tissues and the urine of adult 
AGU mice. In contrast to GlcNAc-Asn, the concentration of Man2GlcNAc2-Asn in brain tissue 
was very low. The accumulation of Man2GlcNAc2-Asn in the liver and spleen of AGU mice was 
found to be age-dependent, being higher in older mice. Enzyme replacement therapy 
administered as i.p. injections of GA, was successful in reducing the accumulation of 
Man2GlcNAc2-Asn and GlcNAc-Asn in non-neuronal tissues and urine of the AGU mice, but 
less effective in brain.   
3. Two bacterial L-asparaginases were shown to hydrolyze β-aspartylpeptides, some of 
which are present in the human body. Both L-asparaginases catalyzed most effectively the 
hydrolysis of β-aspartylpeptide amides; β-aspartylserineamide was hydrolyzed by EcAII and 
ErAII at half of the rate of L-Asn, and the hydrolysis rates of β-aspartylalanineamide and β-
aspartylglycineamide were 1/10-1/50 of that of Asn.  
 
4. Human recombinant glycosylasparaginase was demonstrated to possess antileukaemic 
properties. GA was able to hydrolyze L-asparagine to L-aspartic acid in vitro in cell culture 
medium and inside the cultured EBV-transformed GA-deficient lymphoblasts. Secondly, GA 
was able to induce cell death, especially in B-lineage ALL cells, and also in T-lineage ALL cells 
in vitro in a manner comparable with the two bacterial L-asparaginases used in ALL therapy. 
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Aspartylglycosaminuria (AGU),
an inherited lysosomal storage
disease, is caused by the deficient
activity of a lysosomal enzyme 
glycosylasparaginase (GA).
Loss of GA activity results in the 
accumulation of glycoasparagines 
in tissues leading to progressive 
psychomotor retardation and a shortened 
life span. Currently there is no cure for 
AGU. In this study, the effectiveness of 
enzyme replacement therapy (ERT) with 
human recombinant GA was evaluated in 
the mouse model of AGU. Furthermore, 
the enzymatic properties of GA and 
bacterial asparaginases were compared.
This study reveals new therapeutic
and catalytic properties of human GA
and bacterial asparaginases. 
